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Abstract
Strategies for preventing acute kidney injury (AKI) in patients undergoing abdominal aortic
aneurysm (AAA) repair were explored in a secondary data analysis of 601 patients from a
randomized controlled trial (RCT). Bivariate analyses identified an association between
intraoperative hypotension and postoperative AKI and suggested IV fluids as the best treatment
option over inotropes/vasopressors which increased the odds of AKI (ORcrude=2.5 95%CI 1.25.0), however, our multivariable analysis was non-significant (ORadjusted=1.7 95%CI 0.8-3.7).
Further analysis found angiotensin-converting enzyme inhibitor and angiotensin II receptor
blocker use within 24 hours prior to repair were not associated with postoperative AKI
(ORadjusted=1.3 95%CI 0.8-2.2). Our systematic review of RCT literature failed to identify any
definitive evidence for effective preventive strategies, and our meta-analysis of 6 RCTs
analyzing remote-ischemic preconditioning showed no statistically significant difference (OR 1.2
95%CI 0.4-3.9). Large, multi-centre RCTs are needed to identify preventive strategies for AKI
after AAA repair.
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Summary for Lay Audience
An abdominal aortic aneurysm (AAA) is the ballooning of the aorta in the abdomen caused by a
weakening in the walls of the vessel. Aneurysms can occur in different locations along the aorta
and can negatively affect the supply of blood to the kidneys. The repair of an AAA can cause
stress to the kidneys due to the procedure and/or different drugs resulting in acute kidney injury
(AKI), a significant complication associated with AAA repair. AKI is defined as an abrupt
decline in kidney function. This thesis explores potential strategies for preventing AKI in
patients undergoing AAA repair. We explored this in a secondary data analysis of 601 patients
from a randomized controlled trial (RCT). Statistical analyses identified an association between
low blood pressure during surgery and postoperative AKI. Analyses of the treatments of the low
blood pressure during surgery suggested IV fluids as the possible best treatment option over
inotropes/vasopressors which increased the odds of patients developing AKI after surgery,
however further analysis was non-significant, so the evidence is unclear. Drugs to treat high
blood pressure have been thought to affect the results of patients undergoing AAA repair and
there are conflicting opinions about whether they should be stopped before surgery or not.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are drugs used to
treat high blood pressure and if taken close to surgery, they may increase the risk of low blood
pressure during surgery which is associated with AKI. Our analysis found angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers taken within 24 hours prior to
repair were not associated with postoperative AKI. We conducted a systematic review and metaanalysis of RCT literature, but we did not identify any conclusive evidence for effective
preventive strategies. Future research needs to be conducted to identify preventive strategies for
AKI after AAA repair using randomized trials.
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Chapter 1

1

Introduction

1.1

Thesis Rationale

An abdominal aortic aneurysm (AAA) is a widening or ballooning of the aorta to a diameter ≥
3.0cm.1,2 This condition is often asymptomatic and the risk of rupture increases as the aneurysm
enlarges, typically over 5-5.5cm in size. AAAs are repaired to prevent rupture using either an
open or endovascular (EVAR) approach. A common postoperative complication among AAA
repair patients is acute kidney injury (AKI). The incidence of postoperative AKI following
EVAR ranges from 1% to 19% ; 3,4–6 while the incidence after open repair ranges from 2% to
29.9%.4,7,8–17 AKI is an abrupt decline in kidney function and tends to be underdiagnosed due to
varying definitions.18,19 AKI development postoperatively is associated with significant
morbidity, mortality, length of hospitalization and hospital costs.18,20–24 Potential therapeutic
targets for the prevention of AKI following AAA repair have not been clearly elucidated.
Understanding potential risk factors is fundamental to proposing preventive strategies. There
remains no proven method to prevent AKI following AAA repair and it remains a challenging
unsolved clinical problem.

1.2

Thesis Objectives

Objective 1) To explore potential strategies for the prevention of AKI in patients undergoing
AAA repair
1a) To examine the association of angiotensin-converting enzyme inhibitor and/or
angiotensin II receptor blocker use within 24 hours of AAA repair with AKI (Chapter 3)

1

1b) To examine the association of intraoperative hypotension (SBP < 100mmHg) and its
associated treatments during AAA repair with AKI (Chapter 3)
1c) To identify and evaluate the preventive strategies for AKI tested in randomized
controlled trials available in published literature. (Chapter 4)

1.3

Thesis Outline

The goals of this thesis are to summarize the existing high-quality evidence supporting potential
therapeutic strategies to prevent AKI after AAA repair; and to conduct a secondary data analysis
of the largest randomized controlled trial (RCT) conducted on this topic (curcumin trial –
believed to possess anti-inflammatory and anti-oxidant properties) looking for novel therapeutic
strategies associated with an altered risk of AKI.25
This thesis includes 5 chapters. Chapter 1 is a statement of objectives and brief rationale for the
overall work. The relevant literature concerning abdominal aortic aneurysm repair, acute kidney
injury and potential therapeutic targets for prevention of postoperative AKI among AAA repair
patients is reviewed in chapter 2. Chapter 3 details the results of a secondary data analysis of the
curcumin trial data looking for the potential effects of intraoperative blood pressure management
and preoperative use of ACE inhibitors/ARBs on the odds of AKI after AAA repair. The
analyses reported in chapter 3 are then placed into a broader context in chapter 4 which includes
the methods and results of a systematic review and meta-analysis evaluating the high-quality
literature looking at preventive strategies for AKI after AAA repair. Finally, chapter 5 outlines
the overall conclusions of the work, limitations, and suggested future directions.
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Chapter 2

2

Literature Review

This chapter will include a review of the literature relating to abdominal aortic aneurysm repair,
acute kidney injury, ACE inhibitors and ARBs, intraoperative hypotension and preventive
strategies for AKI among AAA repair patients.

2.1

Abdominal Aortic Aneurysm Repair

The widening or ballooning of the aorta ≥ 3.0cm in diameter is an abdominal aortic aneurysm
(AAA).1,2 AAAs are prevalent among 0.0% to 12.5% of men, and 0.0% to 5.2% of women.3
Among men over the age of 65, 1% of deaths are due to AAAs and are therefore responsible for
over 175,000 deaths worldwide.3 The major risk factors associated with AAAs are smoking,
hypertension, and family history.1,2 The purpose of electively treating AAAs is to prevent rupture
of the aneurysm and the associated 80% mortality rate.1–3 AAA can be treated using either an
open repair or an endovascular repair (EVAR). Open repair is an invasive procedure requiring
the surgeon to enter the abdominal cavity and hand-sew an interposition graft, thus excluding the
aneurysm from circulation; while the endovascular repair or EVAR consists of minimally
invasive surgery with the placement of a stent graft through the femoral artery to exclude the
aneurysm from circulation.1,2 Reports of perioperative mortality in elective open AAA repair
patients ranges from 1 – 4% and major adverse events are reported in 15 - 30% of patients who
tend to have more comorbidities compared with EVAR patients.1 In a meta-analysis of four
RCTs comparing patients who received EVAR and those who received an open repair, 30 day in
hospital mortality was significantly lower among EVAR patients (1.4% vs. 4.2% P<0.0001, OR
6

0.3 95% CI 0.2 to 0.6).4 There appears to be an advantage regarding short-term mortality among
EVAR patients compared with open repair patients, further confirmed in four independent
systematic reviews and/or meta-analyses.4–7 One of the reviews of the short term results from
AAA repair found that EVAR results in less blood loss, shorter hospital stays, lower 30 day
mortality and complication rates compared with open repair patients.7 Although EVAR has
short-term benefits when compared to open repair; it does have some long-term disadvantages.
In the long-term results of the EVAR-1 trial, the largest RCT of open vs EVAR in AAA repair
patients, reintervention rates were higher among EVAR patients, as was long-term mortality.8
These results are confirmed in four independent systematic reviews which found higher longterm all-cause mortality, reintervention and secondary rupture rates in EVAR patients when
compared with open repair patients.4,5,9,10 The inferior long-term results after EVAR are largely
attributed to the loss of aortic seal with secondary aneurysm sac perfusion and risk of secondary
rupture and need for reintervention. Acute kidney injury (AKI) is a major adverse outcome
following AAA repair and occurs frequently following either open or endovascular aortic
aneurysm repair. It is one of the most common postoperative complications following AAA
repair, but tends to be underdiagnosed due to variable definitions of AKI.11

2.2

Acute Kidney Injury

2.2.1 Definition and classification of AKI
Acute kidney injury is the abrupt decline in kidney function.12 Varying definitions have been
used over the years including different sets of criteria and sometimes arbitrary clinical
thresholds. These inconsistencies led to the establishment of the KDIGO criteria, the Kidney
Disease Improving Global Outcomes criteria for AKI definition and classification.12 Using the
7

KDIGO criteria, AKI is defined as any of the following: increase in serum creatinine (SCr) by
0.3 mg/dl (26.5 mol/l) within 48 hours; or increase in SCr to 1.5 times baseline, which is known
or presumed to have occurred within the prior 7 days; or urine volume 0.5 ml/kg/h for 6 hours.12
Glomerular filtration rate (GFR) is the most widely accepted and most useful measure of kidney
function such that SCr and urine output can be used as surrogate measures for changes in GFR. 12
Previous consensus criteria include the Risk, Injury, Failure, Loss, End-Stage Kidney Disease
(RIFLE) and Acute Kidney Injury Network (AKIN) criteria have been further optimized and
combined to form the KDIGO criteria.12–14
AKI is classified according to 3 stages of increasing severity using SCr and/or urine output: the
first stage is defined as an increase of 1.5-1.9 times baseline SCr or 0.3 mg/dl (26.5 mol/l)
increase in SCr; or urine volume 0.5 ml/kg/h for 6-12 hours. The second stage is defined as an
increase of 2.0 – 2.9 times baseline; or urine output of 0.5 ml/kg/h for 12 hours. The third stage
is defined as: an increase of 3.0 times baseline SCr, or increase in SCr to 4.0 mg/dl (353.6
mol/l) or initiation of renal replacement therapy, or in patients < 18 years: decrease in eGFR to
<35 mL/min per 1.73 m2; or urine output of 0.3 ml/kg/h for 24 hours or anuria for 12 hours.12

2.2.2 Mechanisms of AKI
As outlined in the KDIGO consensus, AKI is caused by a number of conditions and through
various mechanisms.12 The risk for AKI development is increased by exposure to factors that
cause AKI and further increased by the presence of potential factors that increase susceptibility. 12
Susceptibilities outlined in the consensus include dehydration or volume depletion, advanced
age, female sex, black race, chronic kidney disease (CKD), chronic disease including congestive
heart failure, diabetes mellitus, cancer, and anemia.12 Potential exposures include sepsis, critical
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illness, circulatory shock, burns, trauma, cardiac surgery (especially cardiopulmonary bypass),
major non-cardiac surgery including vascular surgery, nephrotoxic drugs, and radiocontrast
agents.12 The etiology of AKI in AAA repair is thought to be multifactorial including changes in
renal perfusion, nephrotoxic drugs, ischemia-reperfusion injury, contrast-induced nephropathy,
renal micro-embolization, acute tubular necrosis, hypovolemia and inflammatory and
neuroendocrine stress response to surgery.15–17

2.3

Postoperative AKI among AAA repair patients

Acute kidney injury development in the postoperative setting is associated with significant
morbidity, mortality, length of hospitalization and hospital costs.12,18–22 Patients at increased risk
for AKI after AAA repair are those who have pre-existing chronic kidney disease, hypertension,
diabetes mellitus and who are older.11,16,23–32 A retrospective cohort of 169 open elective
transperitoneal juxtarenal AAA repair patients analyzing predictors for postoperative renal
dysfunction determined technical factors including renal ischemia time, aortic clamp position
and left renal vein division to be the strongest predictors.33 The incidence of AKI in AAA repair
is significantly higher in open repair patients compared with EVAR in a systematic review of
short-term AAA results.34 Castagno et al. performed a retrospective cohort of 146 infrarenal
AAA repair patients that found similar effects with a significant increase in AKI among open
repair patients compared with EVAR.35 Another retrospective cohort of 6516 patients by Wald et
al. found EVAR was associated with lower odds of AKI (OR 0.4, 95% CI 0.3-0.5) and AKI
requiring dialysis (OR 0.3, 95% CI 0.2-0.6).36 This is in contrast with another systematic review
which found no difference between open and EVAR and postoperative AKI incidence.9 A
critical review of the epidemiology of AKI in vascular surgery patients reported incidences of
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AKI in EVAR patients between 5.5% and 18%; and incidences of AKI up to 26% following
open repair of an infrarenal AAA.11 These incidences were both increased in the presence of
significant clinical or surgical complexity.11 EVAR requiring branched or fenestrated devices or
requiring a snorkel or chimney surgical approach increased postoperative AKI incidence to 28%
and 32% respectively.11 Open repair patients requiring repair of a juxtarenal or suprarenal
aneurysm increased postoperative AKI incidence to 47% and 68% respectively compared with
infrarenal aneursyms.11 In a systematic review, postoperative renal impairment among AAA
repair patients was associated with increased mortality risk (HR 1.5, 95% CI, 1.4-1.7).37
Increased mortality is not the only complication of postoperative AKI among the vascular patient
as other morbidities and hospital costs are also associated with this outcome. Patients who
develop postoperative AKI also have higher rates of cardiovascular events including myocardial
infarction, infection, coagulopathy, and long-term risk of end-stage renal disease (ESRD). 11 It
was demonstrated in a retrospective study that patients with postoperative AKI had hospital costs
of $42 600 compared with patients that did not develop AKI and had hospital costs of $26
700.38 As a consequence of postoperative AKI, 0.5% to 2% of elective AAA repair patients
receive hemodialysis which is associated with in-hospital mortality of 25% to 66% of patients.39
AKI has a significant impact on a patient’s outcomes following AAA repair, and identifying
potential strategies to prevent AKI would be beneficial. We examined two potential modifiable
perioperative factors during AAA repair; ACE inhibitor and/or ARB use immediately
preoperatively, and the impact of intraoperative hypotension and its management on the
incidence of AKI after AAA repair.
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2.4

ACE inhibitors and/or ARBs and AKI

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptors blockers (ARB)
are anti-hypertensive drugs used to treat high blood pressure (hypertension) to reduce the long
term risk of cardiovascular morbidity and mortality.40 These drugs exert their effects by
inhibiting the renin-angiotensin-aldosterone system (RAAS) .40 RAAS inhibitors are the most
prescribed drugs within this class, and the most common and relevant are ACE inhibitors and
ARBs.40 ACE/ARBs systemic effect on angiotensin II contributes to the development of
intraoperative hypotension and to AKI through systemic hypotension and inhibition of efferent
renal arteriolar vasoconstriction.41
There is conflicting evidence regarding the use of these drugs preoperatively among patients
undergoing major surgery, some studies suggest discontinuing ACE/ARBs preoperatively while
others found a reno-protective effect associated with their use.11,12,41–51 In the vascular surgery
setting, a number of cohort studies have suggested holding ACE/ARBs on the day of surgery/in
the immediate preoperative setting.11,46,52 In the EVAR setting, preoperative ARB use was
significantly associated with postoperative AKI in a multivariable analysis of 212 patients who
underwent AAA repair between January 2009 and October 2016 (OR 4.1, 95% CI 1.4 – 12.1).53
In a separate study, Pisimisis et al. found a trend towards an association between ACE and AKI
(P = 0.07) among 208 EVAR patients in a retrospective cohort.46 In another retrospective cohort
study of 268 patients, specifically looking at AAA repair, they determined there to be insufficient
evidence to make any conclusions regarding the use of ACE/ARBs in the preoperative setting of
open and EVAR infrarenal AAA repair using propensity score matching.22
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In the cardiac surgery setting, a meta-analysis of ACE/ARB use in the preoperative setting was
conducted that identified a significant increase in odds of AKI and mortality among ACE/ARB
users.54 A narrative review of the effects of the combined use of ACE inhibitors and ARBs
showed an increased risk of AKI.49 A prospective cohort study of 1287 cardiac surgery patients
examined the association between the preoperative use of ACE/ARBs and AKI, assessing both
structural (defined based on peak postoperative levels of urinary biomarkers) and functional
effects (defined based on changes in preoperative and postoperative serum creatinine). It
determined a significant association between ACE/ARBs and structural AKI. 41 A retrospective
cohort study of 1287 patients found a reno-protective effect due to preoperative ACE/ARB use
for aging cardiac surgery patients, therefore completely contradicting the results above.48
Among noncardiac surgery patients, a systematic review concluded using low level evidence that
ACE/ARBs should be held in the perioperative period to limit hypotension.51 Some studies,
reviews and meta-analyses found a protective effect for continuing ACE/ARBs in the
preoperative setting against postoperative AKI.42,45,55
The consensus among this conflicting literature is that currently there is insufficient high-quality
evidence to make a strong recommendation as to whether or not ACE/ARBs should be held
immediately before surgery or given the morning of surgery.42–45,47,50,56 Similarly, the KDIGO
consensus has stated in its recommendations that there is not enough evidence to recommend
discontinuation.12
A major discrepancy between systematic reviews and meta-analyses is that the pooled studies
have different time points of ACE/ARB use, some defined pre-operative use of ACE/ARBs as
within 120 days, some defined it as within 2 weeks and some defined it as within 24 hours.
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These time points analyze very different ideas: prolonged use of ACE/ARB vs. immediate preoperative use ask different questions and use different mechanisms when considering long-term
use vs. anti-hypertensive mechanisms during the intraoperative time period. The ultimate
consensus for all studies is the need for further analysis of the association between these drugs
and AKI, most calling for multi-centre randomized controlled trials using appropriate definitions
of AKI and predefined time points of ACE/ARB administration and dosage. We utilized the data
from a RCT of curcumin versus placebo which was prospectively collected to try and add further
evidence to this question.

2.5

Intraoperative hypotension and AKI

Intraoperative hypotension is a common occurrence during surgery and has been shown to be
statistically associated with adverse outcomes.11,57,58 It can occur as a result of a number of
reasons including general anesthesia, blood loss, or pre-operative or intraoperative use of
different drugs including ACE/ARBs.51,57 There is currently no widely accepted definition of
intraoperative hypotension; different studies define this complication using different measures
such as systolic blood pressure (SBP), mean arterial pressure (MAP), and central venous
pressure (CVP), among others.57,59,60 Despite varying definitions, an association between
intraoperative hypotension and mortality and AKI has been determined in a number of studies
across different types of surgery. 16,59–66 A systematic review of this topic was conducted to
determine if and to what extent intraoperative hypotension disrupts organ perfusion and damages
organs among non-cardiac surgery patients.57 They determined an increased risk for AKI and
mortality at MAP < 80 mmHg for longer than 10 minutes and increased further with increased
duration or with lower MAP.57 They call for future prospective studies looking at specific patient
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populations and a clear definition for hypotension and outcomes, for example using KDIGO to
define AKI.57 The difference between 30 seconds of a MAP of 40 mmHg and 5 minutes of a
MAP of 50mmHg is important. The former is well tolerated for almost all patients while the
latter would be harmful. The intersection between severity of hypotension and duration of
hypotension is an important consideration within intraoperative hypotension research.
Among patients undergoing AAA repair, a number of studies have examined the association
between hypotension and AKI or mortality. Tallgren et al. determined a statistically significant
association between intraoperative hypotension and AKI in a multivariable analysis of 69 AAA
repair patients in a prospective cohort study (OR 8.5, 95% CI 1.8-39.4, P = 0.006).16 Brinkman
et al. determined that the increased duration and prominence of intraoperative hypotension,
defined as MAP 65 mmHg, to be the most significant intraoperative risk factor for the
development of postoperative AKI among 40 open AAA repair patients in a pilot prospective
observational trial.64 In a retrospective cohort of 71 AAA repair patients of both open and
endovascular repair, Yue et al. identified intraoperative hypotension as a significant risk factor
for AKI (OR=6.0, 95% CI 1.2-30.7) according to the RIFLE criteria.67 Intraoperative
hypotension is also significantly associated with significant consequences including 30 day
mortality(OR 6.6, 95% CI 0.7–61.1, P = 0.06) among a retrospective cohort study of 450 open
AAA repair patients.68 Van Waes et al. performed a retrospective cohort study of 890 vascular
surgery patients and determined a significant association between myocardial injury and
intraoperative hypotension (RR 1.8, 99% CI 1.2 - 2.6, P < 0.001).66 They concluded future
studies should include the different treatments for intraoperative hypotension to understand their
influence on the association between intraoperative hypotension and myocardial injury for
evidence-based decisions regarding proper care.66
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Noncardiac surgery studies were conducted to analyze the association between intraoperative
hypotension and AKI or mortality and they all determined a significant increased association. 59–
61,63,65,69,70

Walsh et al. determined hypotension, defined as MAP <55 mmHg was also associated

with postoperative AKI, even for short durations among 33 330 noncardiac surgery patients in a
retrospective cohort study.60 Patients with the longest duration of MAP <55mmHg defined as
greater than 20 minutes had a 1.5 fold increase in risk of AKI or myocardial injury and 2.0 fold
increase in risk for cardiac complications.60 Vernooij et al. performed a retrospective cohort
study of 10 432 noncardiac surgery patients to analyze how different methods for defining
intraoperative hypotension yielded different levels of significance with the outcomes of
postoperative myocardial infarction and AKI.59 They looked at 8 different methods for defining
hypotension including: MAP <50mmHg, MAP <60mmHg, SBP<70mmHg, SBP<90mmHg,
20% and 40% decrease in SBP from baseline, and 20% and 40% decrease in MAP from baseline.
They determined that none of the effect sizes using one of these measures was any stronger than
the others and that future studies should look at SBP compared with MAP for defining
intraoperative hypotension using different cutoffs and durations. They encourage use of more
stringent definitions to determine the most significant outcomes.59 In terms of AKI, they
determined use of MAP < 50 mmHg to yield the most significant odds ratios using definitions
of: presence of intraoperative hypotension, mean duration of hypotension, absolute decrease in
blood pressure and mean episode area under threshold as models for the relationship between
intraoperative hypotension and AKI (standardized OR 1.2 99%CI 1.0-1.4).59 Sun et al.
determined a significant association between intraoperative hypotension, defined using MAP <
55mmHg, and postoperative AKI in a retrospective cohort study of 5127 noncardiac surgery
patients.63 They found patients with a MAP <55mmHg had 2.3 times the odds (95% CI 1.4–4.1)
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of AKI if the duration of hypotension was between 11 and 20 minutes and 3.5 times the odds
(95% CI 1.5–8.3) of AKI if the duration of hypotension was greater than 20 minutes compared
with patients who had 0 minutes of hypotension.63 They call for RCTs analyzing interventions to
treat or prevent intraoperative hypotension and its associated adverse outcomes.63 The American
College of Surgeons – National Surgical Quality Improvement Program used prospectively
collected data on 152 244 general surgery operations in the United States in 2005−2006 which
found among patients at high risk for AKI, periods of MAP <60 mmHg were more common
among patients who developed AKI than among those who did not.70 Cohort studies among
noncardiac surgery patients also determined a significant association between intraoperative
hypotension and mortality in both prospective and retrospective settings (P<0.05).61,65 Monk et
al. in a prospective cohort study of 1064 non cardiac surgery patients found patients with
intraoperative hypotension had 1.04 times the risk per minute of mortality within 1 year of
surgery compared with patients with normal intraoperative blood pressure(P=0.01).61 Sabate et
al. in a prospective multicenter observational cohort study of noncardiac surgery patients found a
significant association with postoperative major adverse cardiac and cerebrovascular
events(P<0.0001).69
An association between pre-operative ACE inhibitors and/or ARB use and intraoperative
hypotension has been proposed in a RCT by Bertrand et al. and a retrospective cohort study by
Brabant et al. in the AAA repair setting.52,62 Bertrand et al. analyzed 37 patients undergoing
major vascular surgery including AAA repair, carotid endarterectomy, and infraguinal
revascularization.52 Brabant et al. analyzed 84 hypertensive patients scheduled for vascular
surgery.62 They determined a statistically significant association and suggested holding
ACE/ARBs in the immediate preoperative setting to limit potential for intraoperative
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hypotension and its associated adverse outcomes(P<0.05).52,62 Studies involving noncardiac
patients determined a similar association and identified intraoperative hypotension as a
significant risk factor for AKI among hospitalized patients (P=0.001).51,71 These results are
questioned in a systematic review which found a protective effect of ACE/ARBs in the
perioperative setting.47 Further research is required to confirm or deny these findings.
Different measures and cutoffs are often used to define intraoperative hypotension and one has
not been proven to be definitively better than any of the others. The duration of intraoperative
hypotension is also an important consideration. Although intraoperative hypotension and its
association with AKI has been extensively studied, different methods to treat intraoperative
hypotension and its effects on AKI have not been clearly elucidated. Our data allow us to
evaluate whether treating intraoperative hypotension primarily with inotropes/vasopressors or
fluid has an added effect on the incidence of AKI after AAA repair.

2.6

Preventive strategies for AKI among AAA repair patients

At this time, a systematic review or meta-analysis has not been conducted to identify or evaluate
potential preventive measures for AKI among AAA repair patients. A number of cohort studies
have been conducted to evaluate interventions or preventive strategies in this setting including
Pisimisis et al. which states that identification of modifiable perioperative risk factors can be
used to determine strategies to improve renal outcomes among AAA repair patients. They
identified contrast volume and ACE inhibitors as possible areas for improvement in a
retrospective cohort study of 208 EVAR patients.72 Tallgren et al. identified hypotension and low
cardiac output as risk factors that could be targeted for preventive strategies among 69 elective
AAA repair patients in a prospective cohort study.16 Mannitol has been suggested to be a
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preventive intervention of interest among AAA repair patients in a number of cohort and RCT
studies.33,73,74 Zabrocki et al. suggest endovascular repair to be considered a preventive strategy
for AKI and call for a large RCT to assess EVAR vs open repair and a bundle of measures and
their effect on reducing AKI following their analysis of 268 AAA repair patients in a
retrospective cohort.22 Contrast agents have been identified as risk factors for AKI and different
methods or timing of administration have been suggested11,58,75
A review by Saratzis et al. describing AKI after EVAR describes the pathophysiology of the
outcome and describes various preventive strategies for AKI.76 They included hydration,
ischemic preconditioning, regional anesthesia and pharmacological agents as preventive
strategies with a low level of evidence, however, this was not a systematic review and it does not
evaluate patients with open repair.76 A systematic review by Zacharias et al. analyzed AKI and
mortality in the perioperative period of major surgery patients, however, they did not include
AAA repair patients.56 Systematic reviews involving AKI as a postoperative outcome of interest
have proven difficult due to a lack of similar definitions.77 A systematic review analyzing
preventive strategies or interventions for AKI among cardiac surgery patients has been
conducted to consolidate the information on this at risk population and a number of targets were
identified for further study.78 A systematic review in the AAA repair setting would be of interest
to determine preventive strategies or interventions to reduce AKI among this at-risk group.

2.7
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Chapter 3
Exploring target areas for development of preventive strategies for
acute kidney injury in patients undergoing abdominal aortic aneurysm
repair

3

To identify target areas for development of preventive strategies for acute kidney injury
following abdominal aortic aneurysm repair, we performed a secondary data analysis of the
curcumin randomized controlled trial. In this secondary data analysis, we assessed the
association between angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker
use within 24 hours of repair with postoperative AKI to examine the proposed effect of these
anti-hypertensive drugs in the preoperative period. We also assessed the association between
intraoperative hypotension and its associated treatments with postoperative AKI. This chapter
consists of four sections including a brief introduction, description of methods, an in-depth report
of results followed by a discussion.

3.1

Introduction

An abdominal aortic aneurysm (AAA) is a widening or ballooning of the aorta in the abdomen
and is associated with high morbidity and mortality.1–4 It can be repaired surgically using an
open or endovascular procedure, however, postoperative acute kidney injury (AKI) remains a
major complication associated with poor outcomes.1–8 Patients with AKI are at increased risk of
morbidity, mortality and length of hospitalization.2–8 Identifying target areas for development of
preventive strategies or treatment options may improve the outcomes of patients following AAA
repair. Risk factors for AKI among AAA repair include pre-existing chronic kidney disease,
advanced age, diabetes, hypertension, congestive heart failure, prolonged renal ischemia time,
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transfusion, open repair, nephrotoxic medications, atheroembolizaition to the kidney,
intraoperative hypotension, preoperative use of angiotensin-converting enzyme (ACE) inhibitors
or angiotensin II receptor blockers (ARB), and statins, among others.1–7,9–12
ACE inhibitors and ARBs are antihypertensive medications which exert their effects by
inhibiting the renin-angiotensin system (RAS). They have been shown to increase the risk of
postoperative AKI in a number of patient settings including after abdominal aortic aneurysm
repair. This association has been largely studied in the cardiac surgery setting and has
demonstrated conflicting results for a positive or negative effect on risk of postoperative AKI. 13–
15

The majority of studies indicate that preoperative use of RAS inhibitors increases the risk for

postoperative AKI among major elective surgery patients including cardiac and vascular
procedures.6,9,11,14–27 However, among non-cardiac surgery studies, preoperative use of ACE
inhibitors and/or ARBs have failed to show a significant increase in risk for postoperative
AKI.17,28 Among a retrospective cohort of 212 endovascular repair patients, ARBs were shown
to be significantly associated with postoperative AKI (OR 4.1 95% CI: 1.4-12.1).11 In another
retrospective cohort study of 208 patients undergoing EVAR, ACE inhibitors showed a trend to
be predictors for AKI (P=0.07).29 There are obvious discrepancies in the literature with different
definitions of AKI in different patient settings, and it is clear that more studies are needed.
Intraoperative hypotension, using varying definitions, has been widely associated with AKI and
postoperative mortality across varying clinical settings, presumably due to its limiting effect on
organ perfusion. The definition and consistent classification of intraoperative hypotension has
not been clearly established in the literature.30,31 For the purpose of this study, intraoperative
hypotension was defined using systolic blood pressure (SBP) with a threshold of <100mmHg,
which has been previously used in a number of other studies.30,31 Hypotension is associated with
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AKI and mortality in non-cardiac and vascular surgery patients.2,20,30–45 Intraoperative treatment
of hypotension include fluids, blood transfusion, inotropes or vasopressors or no treatment at all.
The optimal treatment has not been established. Van Waes et al.36 performed a retrospective
cohort of 890 vascular surgery patients and analyzed the association between intraoperative
hypotension and myocardial injury. They urge future studies to investigate the association
between intraoperative hypotension and its treatments and the interactions associated with these
factors and postoperative outcomes including myocardial injury.36 Sun et al. performed a
retrospective cohort study of 5127 patients undergoing noncardiac surgery and they concluded
that future research is needed to consider the treatments of intraoperative hypotension when
analyzing outcomes including acute kidney injury.38 These suggestions to analyze intraoperative
hypotension treatments were considered in the design of this analysis.
We conducted this secondary data analysis of the curcumin RCT in patients undergoing AAA
repair to understand the association between the use of ACE inhibitors/ARBs immediately prior
to surgery with the risk of AKI after AAA repair; and to explore the association between
intraoperative hypotension and its method of treatment (inotropes/vasopressors, fluids or no
treatment) with the risk of postoperative AKI.

3.2

Methods

3.2.1 Data Source and Sample
The curcumin trial46 was a parallel-group, randomized, placebo-controlled trial of 606 patients
from 10 centres across Canada who underwent an elective AAA repair between November 2011
and November 2014 in hopes of preventing perioperative complications. This is the largest RCT
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to date on the topic of AKI prevention in AAA patients. The inclusion and exclusion criteria for
patient recruitment to this RCT are included in Appendix A. Patients, health care providers and
local research staff were blinded to treatment assignment. The trial was conducted to assess the
effects of perioperative administration of curcumin on the primary outcome of postoperative
inflammatory response and secondary outcomes including acute kidney injury, length of hospital
stay, and a composite of clinical events. Curcumin is a herbal supplement derived from the
turmeric plant and is believed to prevent ischemic reperfusion injury and toxin induced injury
among animal studies and a previous human RCT. The study population included elective adult
patients undergoing either open or endovascular AAA repair. From the overall data set, 5
patients were removed for the purpose of all analyses. Of the 5 patients removed, 4 patients were
removed as they did not receive either open or EVAR rather they converted from the EVAR
procedure to the open and the other patient was missing follow up data on AKI and all of their
information was removed. This study’s strengths included its size relative to comparable
literature, the prospective nature of its data collection, and the adjudication of its outcomes.

3.2.2 ACE inhibitors and/or ARBs
ACE inhibitors and/or ARBs were defined as a dichotomous variable for the purpose of this
study. Patients who received an ACE inhibitor and/or ARB in the 24 hours prior to repair were
compared with patients who did not receive an ACE inhibitor and/or ARB or received an ACE
inhibitor and/or ARB greater than 24 hours prior to repair. For the ACE inhibitor and/or ARB
analysis, 2 additional patients were removed for missing values in the hypertension category.
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3.2.3 Intraoperative hypotension: SBP < 100mmHg
Intraoperative hypotension was defined as a patient whose SBP dropped below 100mmHg during
repair. The analysis was completed using a categorical variable defined according to the
treatment of intraoperative hypotension. Patients were either treated with fluids or
inotropes/vasopressors or received no treatment and were compared with patients who did not
have intraoperative hypotension during repair (i.e. maintained SBP > 100mmHg). For the SBP
<100mmHg analysis, 9 additional patients were removed for missing values in the SBP
<100mmHg and hypertension categories.

3.2.4 AKI
The KDIGO criteria defines acute kidney injury as either: a 0.3mg/dL (or 26.5umol/L)
increase in serum creatinine in the 48 hours following surgery from the pre-operative value, or a
50% increase in serum creatinine the 7 days following surgery from the preoperative value. 5,46
For the purpose of this analysis the primary study outcome, AKI, was represented using the 7
day criteria. AKI was reported as a dichotomous outcome (i.e. yes or no).

3.2.5 Covariates for Multivariable Analyses
The covariates adjusted for in the multivariable analyses were chosen a priori based on existing
literature. Age, pre-existing chronic kidney disease, repair type performed, diabetes,
hypertension, aneurysm size and intraoperative hypotension were adjusted for in the ACE/ARB
analyses. Age, pre-existing chronic kidney disease, repair type performed, diabetes,
hypertension, and aneurysm size were adjusted for in the intraoperative hypotension analyses.
Adjusting for these variables is standard amongst studies of AAA repair patients as well as

32

cardiac and non-cardiac patient settings. Age is overwhelmingly adjusted for in AAA repair
settings looking at AKI, as well as amongst a variety of other surgical settings.
6,7,10,11,13,14,17,19,23,31,32,47,48

Biological sex, hypertension, and diabetes are also controlled for very

often.6,7,10,11,13,14,17,19,23,28,31,32,38,47,49 Pre-operative kidney function is also commonly controlled
for and pre-existing chronic kidney disease is considered to be one of the strongest predictors for
AKI.6,7,38,11,13,14,17,20,23,28,31 The size of the aneurysm is also commonly controlled for as well as
the type of repair performed regarding the repair procedure.10,11Age, years and aneurysm size
(diameter), mm were reported as continuous variables. Preexisting chronic kidney disease was
reported as a dichotomous variable using the estimated glomerular filtration rate (eGFR):
eGFR<60 mL/min/1.73m2 vs eGFR>60 mL/min/1.73m2. Repair type performed was reported as
a dichotomous variable: endovascular repair or open repair. Diabetes (Type I and II) and
hypertension (treated) were also reported as dichotomous variables.

3.2.6 Statistical Analysis
Continuous variables are presented as mean (standard deviation) and categorical variables as
proportions for univariate analyses. Bivariate analyses were conducted using t tests, Pearson chisquare tests, Fisher’s exact tests, or multiple comparisons with Tukey procedures to examine the
relationship between a covariate of interest with ACE inhibitors and/or ARBs, or with
intraoperative hypotension (SBP <100mmHg) and its associated treatments and with the
outcome of AKI. Logistic regression was performed to assess the crude association between the
variables of interest with AKI. Multivariable analyses were conducted between the variables of
interest with AKI and adjusted for pre-identified covariates. We selected covariates for
adjustment based on clinical knowledge and a literature review. The covariates adjusted for
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included age, diabetes, hypertension, pre-existing chronic kidney disease, repair type performed,
aneurysm size and SBP < 100mmHg intraoperatively (for the ACE/ARB analysis only). The
crude and adjusted associations are estimated with odds ratios and 95% confidence intervals.
Two-sided P<0.05 was considered statistically significant for all analyses. Analyses were
performed using SAS software, version 9.4 (SAS Institute, Cary, NC, USA).50 The multivariable
models were evaluated for model fit using the Hosmer-Lemeshow goodness-of-fit statistic.51

3.2.7 Sensitivity Analysis
To account for multiple centres, we used a mixed effects regression with a random intercept to
account for within-centre variability with pre-identified covariates in a multivariable regression
model. We compared the regression estimates with the results of those not adjusted for centre.

3.2.8 Subgroup Analyses
1. We examined the effects of ACE inhibitor and/or ARB use within 24 hours of repair and
AKI within subgroups of open repair vs. EVAR patients. We used the same methods
previously described to determine unadjusted and adjusted odds ratios.
2. We examined the effects of intraoperative hypotension (SBP < 100mmHg) and
associated treatments and AKI within subgroups of open repair vs. EVAR patients. We
used the same methods previously described to determine unadjusted and adjusted odds
ratios.
3. We examined the association between ACE inhibitor and/or ARB use within 24 hours of
repair and postoperative AKI within a subgroup of patients who were prescribed
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ACE/ARBs preoperatively regardless of whether they were taken or held within 24 hours
of repair. We excluded patients who were not prescribed these drugs prior to surgery.

3.2.9 Additional Analyses
We conducted exploratory analyses into potential effect modifiers of any association between
AKI and the variables of interest relative to both ACE inhibitors/ARBs and intraoperative
hypotension.
1. Interaction between ACE inhibitors and/or ARBs within 24 hours of repair and
preexisting chronic kidney disease (CKD)
We examined whether the presence of preexisting CKD (defined by a preoperative eGFR <60
mL/min per 1.73m2) modified the effect of ACE inhibitors and/or ARBs prior to AAA repair
with respect to the risk of AKI. The P value for the interaction was assessed by including the
ACE inhibitor and/or ARB variable (yes/no), an indicator variable for CKD (GFR<60
mL/min/1.73m2 vs 60 mL/min/1.73m2 ) and an interaction variable (CKD x ACE/ARB) as
independent variables in a regression model for binary outcome data.
2. Interaction between SBP < 100mmHg during repair (and associated treatments) and
preexisting chronic kidney disease (CKD)
We examined whether the presence of preexisting CKD (defined by a preoperative eGFR <60
mL/min per 1.73m2) modified the effect of intraoperative hypotension (SBP <100mmHg) and its
associated treatments with respect to the risk of AKI. The P value for the interaction was
assessed by including the SBP <100mmHg variable, an indicator variable for CKD (GFR<60
mL/min/1.73m2 vs 60 mL/min/1.73m2 ) and an interaction variable (CKD x SBP <100mmHg) as
independent variables in a regression model for binary outcome data.
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3. Interaction between SBP < 100mmHg during repair (and associated treatments) and
repair type performed (open vs. EVAR)
We examined whether the repair type performed (open vs. EVAR) modified the effect of SBP <
100mmHg during repair and its associated treatments prior to AAA repair with respect to the risk
of AKI. The P value for the interaction was assessed by including the SBP < 100mmHg variable,
an indicator variable for type of repair (open vs. EVAR) and an interaction variable (repair type
x SBP <100mmHg) as independent variables in a logistic regression model.
4. Mediation Analysis
We performed a mediation analysis to assess whether having intraoperative SBP less than
100mmHg mediated the effect of ACE inhibitors and/or ARBs within 24 hours of repair on AKI.
There is conflicting evidence that suggests intraoperative hypotension is an effect modifier of
this association among non-cardiac surgery patients, however, among AAA repair patients
intraoperative hypotension was significantly associated with AKI among patients taking ACE
inhibitors and/or ARBs.20–22,52,53 A detailed description of mediation methods are included in
Appendix B.

3.3

Results

3.3.1 Descriptive statistics
Table 3-1 shows baseline characteristics of patients undergoing a AAA repair including
demographics, comorbidities and laboratory investigations (N=601). The overall sample
(N=601) had a mean age of 75.5 years (8.0), ranging from 51 to 95 years and consisted of a
higher proportion of males (82.5%) than females (17.5%). The majority of patients underwent
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their AAA repair at London Health Sciences Centre (34.4%) and University of Alberta Hospital
– Edmonton (29.3%). In terms of comorbidities, most patients had hypertension (76.3%) and
many had coronary artery disease (39.0%), were current smokers in the past 30 days (30.8%) or
had chronic obstructive pulmonary disease (27.9%) and diabetes mellitus (24.0%). Patients had a
mean preoperative serum creatinine of 94.1mol/L (34.2).
Table 3-1 Baseline characteristics of patients undergoing an elective AAA repair.
Frequency (%)
Demographics
Age, years
Sex, male
Centre
London - LHSC
Edmonton - UAH
Ottawa - OH
Hamilton - HHS
Winnipeg - SBH
Toronto – SMH
Sudbury - HSN
Toronto – Sunnybrook
Calgary - PLC
Montreal - HSC
Comorbidities
Congestive heart failure
Coronary artery disease
Chronic obstructive pulmonary disease
Current smoker (Past 30 days)
Hypertension
Diabetes mellitus
Previous cerebrovascular event
Pre-existing chronic kidney disease
(GFR < 60 mL/min/1.73m2)
Aneurysm size, mm
Laboratory Investigations
Preoperative GFR, mL/min/1.73m2
Preoperative serum creatinine, mol/L
N=601

Mean (SD)
75.5, (8.0)

496 (82.5%)
207 (34.4%)
176 (29.3%)
51 (8.5%)
51 (8.5%)
34 (5.7%)
18 (3%)
22 (3.7%)
16 (2.7%)
15 (2.5%)
11 (1.8%)
27 (4.5%)
233 (39.0%)
165 (27.9%)
185 (30.8%)
457 (76.3%)
144 (24.0%)
77 (12.9%)
191 (31.8%)
58.5, (9.0)
69.6, (19.6)
94.1, (34.2)

1 patient missing congestive heart failure information, 3 patients missing coronary artery disease information, 10
patients missing chronic obstructive pulmonary disease information, 1 patient missing current smoker information, 2
patients missing hypertension information, 4 patients missing previous cerebrovascular event information.
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SD, standard deviation, LHSC, London health sciences centre, OH, Ottawa hospital, SMH, St. Michael’s hospital,
HSN, health sciences north, UAH, university of Alberta, PLC, Peter Lougheed centre, SBH, St. Boniface hospital,
HHS, Hamilton health sciences, HSC, health sciences centre, GFR, glomerular filtration rate.

Table 3-2 presents operative details of patients undergoing an AAA repair including
characteristics specific to open and endovascular repair. The type of repair performed was fairly
evenly split with 46.9% of patients undergoing an open repair and 53.1% of patients undergoing
an endovascular repair. Of the open repair group most patients had their clamp in the infrarenal
position (75.8%) and an overall mean of 55 minutes (28.1). Of the endovascular repair group
fluoroscopy was used among 96.5% of patients with an overall mean duration of 12.7 minutes
(21.8).
Table 3-2 Operative details of patients undergoing an AAA repair
Frequency (%)
Type of repair performed
Open
Endovascular
Blood transfusion, units
IV contrast
Renal revascularization
Lower limb revascularization
Mannitol
Furosemide
Open Repair Only (N=282)
Clamp position*
Above and Below
Infrarenal
Suprarenal
Cross clamp duration, minutes
Cell saver blood, mL
Endovascular Repair Only (N=319)
Fluoroscopy used
Fluoroscopy time, minutes
N=601

Mean (SD)

282 (46.9%)
319 (53.1%)
1.5, (3.2)
315 (52.7%)
50 (9.2%)
63 (11.7%)
34 (5.7%)
9 (1.5%)

21 (7.6%)
210 (75.8%)
46 (16.6%)
55, (28.1)
640.6, (595.7)
302 (96.5%)
12.7, (21.8)

3 patients missing IV contrast information , 58 patients missing renal revascularization information, 62 patients
missing lower limb revascularization information, 3 patients missing mannitol information, 8 patients missing
furosemide information, *5 patients missing clamp position, 6 patients missing fluoroscopy information.
SD, standard deviation, IV, intravenous.
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Clinical outcomes of all 601 patients are described in Table 3-3. AKI developed postoperatively
in 13.1% of all patients by 7 days postoperatively. There were 4 competing events of death in the
overall sample. Patients who developed postoperative AKI were classified according to 3 stages
with most falling in Class 1, at 74.8% of those who developed AKI. A total of 79 patients were
diagnosed with AKI in the first 7 days postoperatively and were classified according to the
“KDIGO – kidney disease improving global outcomes” criteria.5 Dialysis was a rare outcome
with 6 patients requiring this intervention (1.0%) and of the overall sample 14 died (2.3%), 9 of
which died within 30 days of surgery (1.5%). The mean hospital stay was 5.8 days (5.4).
Table 3-3 Clinical outcomes of patients who underwent an AAA repair
Frequency (%)
Acute kidney injury (KDIGO)
Total
Stage 1
Stage 2
Stage 3
Dialysis
Death
30 days after surgery*
Other Complications
Myocardial infarction
Sepsis/Infection
Pneumonia
Major bleed
Peptic ulcer
Non-fatal cardiac arrest
Stroke
Deep vein thrombus
Pulmonary embolus
Congestive heart failure
Lower limb amputation
Ischemic bowel
Hospital stay, days
N=601

Mean (SD)

79 (13.1%)
59 (9.8%)
11 (1.8%)
9 (1.5%)
6 (1.0%)
14 (2.3%)
9 (1.5%)
19 (3.2%)
6 (1.0%)
7 (1.2%)
15 (2.5%)
3 (0.5%)
5 (0.8%)
2 (0.3%)
1 (0.2%)
4 (0.7%)
7 (1.2%)
1 (0.2%)
4 (0.7%)
5.8, (5.4)

*5 patients missing “death 30 days after surgery” information.
SD, standard deviation, KDIGO, kidney disease improving global outcomes.
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Characteristics of patients with (N=79) and without postoperative AKI (N=522) are described in
Appendix C. Patients without AKI were significantly older than patients with AKI. Patients
without AKI were significantly more likely to be male than patients with AKI. Patients with AKI
were significantly more likely to have preoperative hypertension than patients without AKI .
Patients with AKI were significantly more likely to have an open repair, rather than an
endovascular repair. Patients with AKI were significantly more likely to have pre-existing CKD
than patients without AKI. Patients who developed postoperative complications were
significantly more likely to have also developed postoperative AKI. Patients who developed
postoperative AKI had significantly higher mortality than those who didn’t develop AKI.

3.3.2 ACE inhibitors and/or ARBs
The data set used to analyze ACE inhibitors and/or ARBs with postoperative AKI are comprised
of a sample of 599 patients. The demographics, comorbidities, laboratory measurements,
operative details and outcomes are summarized in Table 3-4. Patients who took ACE inhibitors
and/or ARBs in the 24 hours prior to repair were significantly more likely to also have
preoperative diabetes mellitus compared with patients who did not take ACE inhibitors and/or
ARBs in the 24 hours prior to repair. Patients with preoperative hypertension were significantly
more likely to receive ACE inhibitors and/or ARBs in the 24 hours prior to repair compared with
those who did not receive them. Patients with preoperative congestive heart failure were also
significantly more likely to take ACE inhibitors and/or ARBs in the 24 hours prior to repair
compared to those that did not. Patients who took ACE inhibitors and/or ARBs in the 24 hours
prior to AAA repair were not significantly more at risk for AKI however they had significantly
higher mortality.
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Table 3-4. Baseline Demographics of patients taking ACE inhibitors and/or ARBs or not
taking ACE inhibitors and/or ARBs in the 24 hours prior to AAA repair

Demographics
Age (years) mean, SD
Sex, male No. (%)
Comorbidities
DM No. (%)
HTN No. (%)
CHF No. (%)
CAD No. (%)
COPD No. (%)
Previous CVE No. (%)
Current Smoker (Past 30
days) No. (%)
Pre-existing chronic
kidney disease (GFR <
60 mL/min/1.73m2)
SCr (mol/L) mean, SD
eGFR categories
(mL/min/1.73m2) No.
(%)
<30
30 to 45
46 to 60
>60
Operative Details
Type of repair No. (%)
Open
EVAR
Aneurysm size (mm)
mean, SD
Outcomes
AKI – Total
Stage 1
Stage 2
Stage 3
Complications** No.
(%)
Death*** No. (%)

ACE/ARB (yes)
N=172

ACE/ARB (no)
N=427

P Value

75.9, 7.5
147 (85.5%)

75.4, 8.1
347 (81.3%)

0.51
0.22

56 (32.6%)
165 (95.9%)
15 (8.8%)
76 (44.7%)
44 (26.0%)
29 (17.1%)

86 (20.1%)
292 (68.4%)
12 (2.8%)
156 (36.6%)
120 (28.6%)
48 (11.3%)

0.001
<0.0001
<0.01
0.07
0.54
0.06

49 (28.5%)

136 (31.9%)

0.41

60 (34.9%)

131 (30.7%)

0.32

96.0, 32.3

93.4, 35.1

0.41

0.553
4 (2.3%)
18 (10.5%)
38 (22.1%)
112 (65.1%)

15 (3.5%)
39 (9.2%)
77 (18.0%)
296 (69.3%)

74 (43.0%)
98 (57.0%)

207 (48.5%)
220 (51.5%)

0.23

56.5, 14.1

58, 10.4

0.24

28 (16.3%)
21 (12.2%)
2 (1.2%)
5 (2.9%)

51 (11.9%)
38 (8.9%)
9 (2.1%)
4 (0.9%)

0.16

17 (9.9%)

37 (8.7%)

0.64

6 (3.5%)

3 (0.7%)

0.02

0.15

1 patient missing CHF information, 3 patients missing CAD information, 10 patients missing COPD information, 4
patients missing previous CVE information, 1 patient missing current smoker information, 5 patients missing death
information. , **Complications include new acute dialysis, myocardial infarction, percutaneous coronary
intervention, coronary artery bypass graft, sepsis, pneumonia, non-fatal cardiac arrest, stroke, deep vein thrombosis,
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pulmonary embolism, lower limb amputation, ischemic bowel, congestive heart failure, death within 30 days of
surgery), *** death within 30 days of surgery.
ACE, angiotensin-converting enzyme inhibitor, ARB, angiotensin II receptor blocker, AAA, abdominal aortic
aneurysm repair, SD, standard deviation, No. number, DM, diabetes mellitus, HTN, hypertension, CHF, congestive
heart failure, CAD, coronary artery disease, COPD, chronic obstructive pulmonary disease, CVE, cerebrovascular
event, SCr, serum creatinine, GFR, glomerular filtration rate, AKI, acute kidney injury.

3.3.3 Intraoperative hypotension: SBP <100mmHg
The data set used to analyze SBP < 100mmHg and its associated treatments with postoperative
AKI were comprised of a sample of 593 patients. The demographics, comorbidities, laboratory
measurements and operative details are summarized in Table 3-5. Patients who had an
intraoperative SBP < 100mmHg and were treated with fluids were significantly more likely to be
older compared with patients who did not have an intraoperative SBP < 100mmHg. Repair type
performed and intraoperative SBP < 100mmHg treatment were significantly related. Of the 157
patients that did not have an intraoperative SBP < 100mmHg, 77.7% of them had an EVAR.
Aneurysm size (mm) and SBP < 100mmHg with associated treatments were significantly related.
Patients who had intraoperative SBP < 100mmHg were significantly more at risk for AKI
compared with patients who had SBP > 100mmHg. Patients treated with vasopressors comprised
50% of the 79 patients with AKI.
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Table 3-5. Baseline demographics of patients with intraoperative hypotension (SBP
<100mmHg) during AAA repair
SBP >
100mmHg

SBP < 100mmHg

N=157

No
Treatment
N=85

Fluids
N=108

Inotropes/
Vasopressors
N=243

P
Value

77.2, 7.7

74.5, 7.9

74.5, 7.8

75.3, 8.1

0.02 (2
vs 0)

132 (84.1%)

70 (82.4%)

87 (80.6%)

201 (82.7%)

0.91

39 (24.8%)
123
(78.3%)
11 (7.1%)
61 (39.4%)
53 (34.2%)

22 (25.9%)

24 (22.2%)

55 (22.6%)

0.89

70 (82.4%)

84 (77.8%)

175 (72.0%)

0.20

3 (3.5%)
34 (40.5%)
24 (29.3%)

2 (1.9%)
36 (33.3%)
31 (29.3%)

11 (4.5%)
101 (41.6%)
55 (22.8%)

0.26
0.54
0.10

11 (13.3%)

8 (7.5%)

31 (12.8%)

0.15

28 (33.3%)

37 (34.3%)

79 (32.5%)

0.28

22 (25.9%)

29 (26.9%)

79 (32.5%)

0.21

90.9, 27.8

88.2, 27.2

95.7, 34.9

0.13

1 (1.2%)
10 (11.8%)
11 (12.9%)
63 (74.1%)

1 (0.9%)
9 (8.3%)
19 (17.6%)
79 (73.2%)

11 (4.5%)
21 (8.6%)
47 (19.3%)
164 (67.5%)

0.38

45 (52.9%)
40 (47.1%)

64 (59.3%)
44 (40.7%)

131 (53.9%)
112 (46.1%)

<0.0001

56.8, 14.1

57.7, 12.5

59.2, 9.1

0.02 (3
vs 0)

Demographics
Age mean, SD
Sex male No.
(%)
Comorbidities
DM No. (%)
HTN No. (%)

CHF No. (%)
CAD No. (%)
COPD No. (%)
Previous CVE
27 (17.2%)
No. (%)
Current smoker
39 (24.8%)
(Past 30 days)
No. (%)
Pre-existing
58 (36.9%)
chronic kidney
disease
Laboratory Measurements
SCr (mol/L)
96.7, 37.2
mean, SD
eGFR categories
(mL/min/1.73m2
) No. (%)
5 (3.2%)
<30
16
(10.2%)
30 to 45
37 (23.6%)
46 to 60
99 (63.1%)
>60
Operative
Details
Type of repair
No. (%)
35 (22.3%)
Open
122 (77.7%)
EVAR
Aneurysm size
55.5, 11.6
(mm) mean, SD
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Outcomes
AKI – Total
Stage 1
Stage 2
Stage 3
Complications*
* No. (%)
Death*** No.
(%)

11 (7.0%)
9 (5.7%)
0 (0%)
2 (1.3%)

15 (17.7%)
10 (11.8%)
4 (4.7%)
1 (1.2%)

12 (11.1%)
8 (7.4%)
3 (2.8%)
1 (0.9%)

38 (15.6%)
31 (12.8%)
3 (1.2%)
4 (1.7%)

0.04

10 (6.4%)

11 (12.9%)

6 (5.6%)

24 (9.9%)

0.19

2 (1.3%)

3 (3.5%)

0 (0%)

2 (0.8%)

0.13

0.07

1 patient missing CHF information, 3 patients missing CAD information, 9 patients missing COPD information, 4
patients missing previous CVE information, 5 patients missing death information. , **Complications include new
acute dialysis, myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, sepsis,
pneumonia, non-fatal cardiac arrest, stroke, deep vein thrombosis, pulmonary embolism, lower limb amputation,
ischemic bowel, congestive heart failure, death within 30 days of surgery), *** death within 30 days of surgery.
SBP, systolic blood pressure, AAA, abdominal aortic aneurysm repair, SD, standard deviation, No. number, DM,
diabetes mellitus, HTN, hypertension, CHF, congestive heart failure, CAD, coronary artery disease, COPD, chronic
obstructive pulmonary disease, CVE, cerebrovascular event, SCr, serum creatinine, eGFR, estimated glomerular
filtration rate, EVAR, endovascular, AKI, acute kidney injury.

3.3.4 Bivariate and Multivariable Logistic Regression Models
Table 3-6 presents the results of the multivariable models for ACE inhibitors and/or ARBs and
for intraoperative SBP < 100mmHg. The ACE inhibitors and/or ARBs model was adjusted for
age, pre-existing CKD, repair type performed (open vs. EVAR), diabetes, hypertension,
intraoperative SBP < 100mmHg and aneurysm diameter. These variables were chosen as they are
based on substantive theory from clinical knowledge and literature review. Diabetes and
hypertension were significantly associated with ACE inhibitors and/or ARBs. ACE inhibitors
and/or ARBs were not significantly independently associated with AKI. The 95% CI of 0.8 to
2.2 spans 1.0, therefore the increased odds (OR 1.3) of AKI among patients who took ACE
inhibitors and/or ARBs within 24 hours of repair compared with patients who did not was not
statistically significant. Neither the crude nor adjusted odds ratio were statistically significant.
The ACE inhibitor and/or ARB model fit the data satisfactorily with a nonsignificant HosmerLemeshow goodness-of-fit test (P=0.54). Bivariate analyses determined statistically significant
associations between select treatments for intraoperative hypotension and AKI postoperatively.
Patients who did not receive treatment for SBP <100mmHg during repair had 2.8 (95% CI 1.244

6.5) greater odds of postoperative AKI compared with those who maintained SBP > 100mmHg
in the bivariate logistic regression. Patients who received inotropes or vasopressors for SBP
<100mmHg during repair had 2.5 (95% CI 1.2-5.0) greater odds of postoperative AKI compared
with those who maintained SBP > 100mmHg in the bivariate logistic regression. The bivariate
analyses did not detect a significant association between fluid treatment of intraoperative
hypotension and postoperative AKI. The intraoperative SBP <100mmHg and associated
treatments model was adjusted for age, pre-existing CKD, repair type performed (open vs.
EVAR), diabetes, hypertension and aneurysm diameter. These variables were also chosen based
on substantive theory from clinical knowledge and literature review. Age, type of repair and
aneurysm size (mm) were significantly associated with type of treatment for intraoperative
hypotension. None of the levels of the SBP <100mmHg exposure variable was significantly
independently associated with AKI in the multivariable analyses. The 95% CI for all 3 levels of
odds ratios include 1.0, therefore the increased odds of AKI among patients who received fluids,
inotropes/vasopressors or no treatment for an intraoperative SBP < 100mmHg compared with
patients with intraoperative SBP >100mmHg was not statistically significant. The SBP model fit
the data satisfactorily with a nonsignificant Hosmer-Lemeshow goodness-of-fit test (P=0.43).
The assessment of multicollinearity for each model produced variance inflation factors all lower
than two indicating no concern regarding this assumption for multivariable logistic regression.
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Table 3-6 Bivariate and Multivariable Logistic Regression of ACE inhibitors and/or ARBs
and SBP < 100mmHg and AKI
Crude Odds Ratio
(95% CI)
1.4 (0.9 – 2.4)

Adjusted Odds Ratio
(95% CI)
1.3 (0.8 – 2.2)

No treatment

2.8 (1.2-6.5)

2.0 (0.8 – 4.8)

Fluids

1.7 (0.7-3.9)

1.0 (0.4 – 2.6)

Exposure
ACE/ARB*
SBP < 100mmHg**

Inotropes/Vasopressors
2.5 (1.2-5.0)
1.7 (0.8 – 3.7)
* Adjusting for Age, Pre-existing CKD, Repair Type Performed (Open vs. EVAR), DM, HTN, intraoperative SBP <
100 mmHg, and Aneurysm Diameter
** Adjusting for Age, Pre-existing CKD, Repair Type Performed (Open vs. EVAR), DM, HTN, and Aneurysm
Diameter
ACE, angiotensin-converting enzyme inhibitor, ARB, angiotensin II receptor blocker, SBP, systolic blood pressure,
AKI, acute kidney injury, CI, confidence interval, CKD, chronic kidney disease, EVAR, endovascular abdominal
aortic aneurysm repair, DM, diabetes mellitus, HTN, hypertension.

3.3.5 Sensitivity Analysis
The adjusted odds ratios further adjusted to account for centre are summarized in Appendix D
contrasted with the adjusted odds ratio without accounting for centre. The odds ratios and 95%
CI remain relatively similar indicating that centre did not significantly affect the results of the
multivariable analyses.

3.3.6 Subgroup Analysis
Among 275 open repair patients, 58 patients developed postoperative AKI. Among 318 EVAR
patients, 18 developed postoperative AKI. Therefore, the multivariable results should be
interpreted with extreme caution as there were too few events per variable. Table 3-7 and 3-8
presents that none of the point estimates, neither crude nor adjusted, was statistically significant
as they were underpowered to detect a difference. However, the point estimates for no treatment
and inotropes/vasopressors was higher in open repair patients compared with EVAR patients.
Among EVAR patients, the odds ratio for inotropes/vasopressors suggests a potentially
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protective effect against AKI (OR 0.8 95% CI 0.3 – 2.5) compared with patients who did not
have intraoperative hypotension (SBP < 100mmHg) as shown in Table 3-8.
Table 3-7. Crude and Adjusted Odds Ratios of ACE inhibitors and/or ARBs and
Intraoperative Hypotension (SBP < 100mmHg) and AKI among Open Repair Patients
Crude Odds Ratio
(95% CI)
1.4 (0.8 – 2.7)

Adjusted Odds Ratio
(95% CI)
1.5 (0.5 – 4.1)

No treatment

2.8 (0.8 – 9.7)

3.4 (0.8 – 4.8)

Fluids

1.4 (0.4 – 5.0)

1.7 (0.5 – 5.9)

Exposure
ACE/ARB*
SBP < 100mmHg**

Inotropes/Vasopressors
2.5 (0.8 – 7.6)
2.8 (0.9 – 9.0)
* Adjusting for Age, Pre-existing CKD, DM, HTN, intraoperative SBP < 100 mmHg, and Aneurysm Diameter
** Adjusting for Age, Pre-existing CKD, DM, HTN, and Aneurysm Diameter
ACE, angiotensin-converting enzyme inhibitor, ARB, angiotensin II receptor blocker, SBP, systolic blood pressure,
AKI, acute kidney injury, CI, confidence interval, CKD, chronic kidney disease, EVAR, endovascular abdominal
aortic aneurysm repair, DM, diabetes mellitus, HTN, hypertension.

Table 3-8. Crude and Adjusted Odds Ratios of ACE inhibitors and/or ARBs and
Intraoperative Hypotension (SBP < 100mmHg) and AKI among EVAR Patients
Crude Odds Ratio
(95% CI)
1.9 (0.7 – 4.9)

Adjusted Odds Ratio
(95% CI)
1.2 (0.6 – 2.4)

No treatment

1.3 (0.3 – 5.4)

1.3 (0.3 – 5.5)

Fluids

0.8 (0.2 – 3.9)

0.6 (0.1 – 3.3)

Exposure
ACE/ARB*
SBP < 100mmHg**

Inotropes/Vasopressors
0.9 (0.3 – 2.9)
0.8 (0.3 – 2.5)
* Adjusting for Age, Pre-existing CKD, DM, HTN, intraoperative SBP < 100 mmHg, and Aneurysm Diameter
** Adjusting for Age, Pre-existing CKD, DM, HTN, and Aneurysm Diameter
ACE, angiotensin-converting enzyme inhibitor, ARB, angiotensin II receptor blocker, SBP, systolic blood pressure,
AKI, acute kidney injury, CI, confidence interval, CKD, chronic kidney disease, EVAR, endovascular abdominal
aortic aneurysm repair, DM, diabetes mellitus, HTN, hypertension.

Of the 599 patients included in the overall patient sample, 358 patients were prescribed ACE
inhibitors or ARBs prior to surgery. Among those 358 patients prescribed ACE inhibitors or
ARBs prior to surgery, 172 patients received ACE/ARBs within 24 hours prior to repair and 186
patients did not receive ACE/ARBs within 24 hours prior to repair (i.e. they were held). In a
subgroup analysis of the 358 patients prescribed ACE/ARBs preoperatively, 51 patients
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developed postoperative AKI. Therefore, the multivariable results should be interpreted with
extreme caution as there were too few events per variable. Table 3-9 presents that none of the
point estimates, neither crude nor adjusted, was statistically significant as they were
underpowered to detect a difference.
Table 3-9. Crude and Adjusted Odds Ratios of ACE inhibitors and/or ARBs and AKI
among patients prescribed ACE inhibitors and/or ARBs prior to surgery
Exposure
ACE/ARB*

Crude Odds Ratio
(95% CI)
1.4 (0.8 – 2.5)

Adjusted Odds Ratio
(95% CI)
1.6 (0.8 – 2.9)

* Adjusting for Age, Pre-existing CKD, DM, HTN, intraoperative SBP < 100 mmHg, and Aneurysm Diameter

3.3.7 Additional Analyses
The possible interaction between intraoperative hypotension treatments and type of repair
performed was not statistically significant (P=0.4, P=0.5, P=0.2). The possible interaction
between ACE inhibitor and/or ARB use within 24 hours of repair and pre-existing chronic
kidney disease was not statistically significant (P=0.98). The possible interaction between
intraoperative hypotension treatments and pre-existing chronic kidney disease was not
statistically significant (P=0.5, P=0.9, P=0.6).
The results of the mediation analysis of ACE inhibitors and/or ARBs effect on AKI mediated by
SBP <100mmHg during repair are presented in Table 3-10. The estimated direct effect odds ratio
of ACE inhibitor and/or ARB use was 1.3 and the indirect effect mediated by SBP <100mmHg
during repair was 1.0. Large sample (Wald) and bootstrap (1000) confidence intervals are
provided. None of the effects was statistically significant. 3.7% of the total effect of treatment
was mediated by SBP <100mmHg during repair, however again these results were not
statistically significant and cannot be interpreted.
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Table 3-10. Mediation analysis of ACE inhibitors and/or ARBs effect on AKI mediated by
SBP <100mmHg during repair

Estimate

Wald 95%
Confidence Interval

Bootstrap 95%
Confidence Interval

P value

Odds ratio total
effect (TE)

1.3

0.6-2.0

0.7-2.3

0.41

Odds ratio natural
direct effect (NDE)

1.3

0.6-2.0

0.7-2.3

0.42

Odds ratio natural
indirect effect (NIE)

1.0

0.97-1.04

0.98-1.07

0.62

Percentage mediated
(%)

3.7

-11.9-19.4

-7.8-510.7

0.64

ACE, angiotensin-converting enzyme inhibitor, ARB, angiotensin II receptor blocker, SBP, systolic blood pressure,
AKI, acute kidney injury,

3.4

Discussion

Among patients undergoing AAA repair taking an ACE inhibitor and/or ARB within 24 hours
prior to repair, we observed no significant association in the odds of postoperative AKI in users
compared to non-users. Among patients undergoing AAA repair who had intraoperative
hypotension (SBP < 100mmHg) and received either fluids, inotropes/vasopressors or no
treatment, we observed that patients who were treated with inotropes/vasopressors had higher
odds of AKI when compared to those without hypotension. Patients who received no treatment
also had higher odds of AKI compared with patients who did not experience intraoperative
hypotension. Among patients who were treated with fluids, we observed no statistically
significant association in the odds of postoperative AKI compared with patients who did not
experience hypotension. After adjustment for pre-identified covariates none of the odds ratios
was statistically significant, however the direction of effect remained the same suggesting a
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possible trend of an association between patients who received inotropes/vasopressors or no
treatment for intraoperative hypotension with AKI compared with patients who did not
experience intraoperative hypotension. These results were not statistically significant and were
underpowered to detect a difference. Patients who have prolonged hypotension are conceivably
at increased risk for AKI through the development of acute tubular necrosis due to
hypoperfusion.40 The addition of inotropes and vasopressors may further exacerbate this through
vasoconstriction of the arterioles at the nephron level.40 It is conceivable that the association we
observed in the un-adjusted analysis has a biologic rationale and may require further work with a
larger dataset to substantiate the claim. Our data suggests the possibility that intraoperative
hypotension may be treated with fluids preferentially over inotropes/vasopressors to prevent
AKI, but this needs to be further evaluated in a dedicated, well powered RCT.
This study performed a secondary data analysis of an RCT of patients who underwent an AAA
repair. The frequency of AKI among the 601 patients included was 13.1%, which falls within the
range of incidences reported in most studies.1–6,8,10 In our analysis we found age, sex,
hypertension, pre-existing chronic kidney disease, and open repair type to be significantly
associated with AKI. Patients with AKI were also more likely to have other postoperative
complications and had higher mortality. Our bivariate and multivariable logistic regression of
ACE inhibitor and/or ARB use did not demonstrate a statistically significant association with
AKI in either analysis (ORcrude=1.4 95% CI 0.9-2.4, ORadjusted=1.3 95% CI 0.8-2.2). There is
conflicting evidence as to whether these drugs increase or decrease the risk of AKI among AAA
repair patients and there is no clear consensus on whether to hold or give the drugs in the
preoperative period.5,11,28,29,49 Among vascular surgery patients, holding ACE/ARB
preoperatively has been suggested amongst a few cohort studies.29,49 Zabrocki et al. determined a
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nonsignificant association between use of ACE/ARBs in the preoperative setting and open vs
EVAR in a retrospective cohort study of 268 AAA repair patients.6 Pisimisis et al found a trend
towards an association between ACE inhibitors and AKI among 208 EVAR patients in a
retrospective cohort study.29 Bertrand et al performed a RCT of 37 vascular surgery patients
randomized to discontinued ACE/ARBs on the day before surgery vs ACE/ARBs given 1 hour
before surgery and they recommend discontinuing the drugs on the day before surgery.21 Statius
van eps et al determined a significant association between ACE/ARB use and postoperative AKI
(OR 4.1 95% CI 1.4 – 12.1) among a retrospective cohort 212 EVAR patients.11 Interaction
between ACE inhibitors and/or ARBs and pre-existing CKD on AKI was not statistically
significant. Intraoperative hypotension did not demonstrate a statistically significant result as a
mediator between ACE inhibitors and/or ARBs within 24 hours of repair and postoperative AKI.
This is in contrast to prior literature that showed a significant association, however, a systematic
review of noncardiac surgery patients failed to come to a conclusion as to whether or not to hold
ACE inhibitors and/or ARBs prior to surgery to prevent AKI and other major complications.20–
22,52,53

Our data would suggest that holding ACE inhibitors/ARBs is not necessary, however, we

acknowledge the limitations of our analysis such that although we could separate those patients
who were not on the drugs prior to surgery from those that simply held the drug the day before
surgery, our analysis was underpowered to detect a difference.
Our multivariable logistic regression analyses of intraoperative hypotension (SBP <100mmHg)
treatments and AKI were not statistically significant. However, the crude odds ratios from the
bivariate analyses for inotrope/vasopressors (ORcrude=2.5 95% CI 1.2-5.0, ORadjusted=1.7 95% CI
0.8-3.7) or no treatment (ORcrude=2.8 95% CI 1.2-6.5, ORadjusted=2.0 95% CI 0.8-4.8) were
statistically significant and although the adjusted odds ratio were not, the direction of effect
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remained unchanged. The confidence intervals for these two adjusted point estimates are wide
indicating that further studies of these effects could be done with larger sample sizes to
determine a precise estimate. Interaction between intraoperative hypotension and pre-existing
CKD on AKI was not statistically significant. Interaction between intraoperative hypotension
and repair type performed on postoperative AKI was not statistically significant. This is in
contrast to relevant studies that demonstrated a statistically significant association between
intraoperative hypotension and AKI among AAA repair patients.2,33,34 Among open repair
patients, Tallgren et al. (N=69), Davidovic et al. (N=450), and Brinkman et al.(N=40) all
determined a significant association between intraoperative hypotension and AKI in prospective
and retrospective cohort studies.2,34,35 Brinkman et al. found a significant association between
duration and severity of intraoperative hypotension and postoperative AKI in a pilot prospective
observational trial of 40 patients undergoing open AAA repair (P=0.04, P=0.01).34 Yue et al.
found intraoperative hypotension to be a significant predictor of AKI in a retrospective cohort of
71 critically ill open and EVAR AAA repair patients (OR 6.0 95% CI 1.2 – 30.7).33 However,
Macedo et al found no significant differences in rates of hypotension and AKI during open repair
of thoracoabdominal and AAA repair in a cohort of 77 patients.45 To our knowledge, our study is
the first analysis of intraoperative hypotension’s associated treatments and postoperative AKI
among AAA repair patients.
Efforts to reduce postoperative AKI would be beneficial in this patient setting to minimize risk
of further morbidities and mortality. The target areas of this analysis were use of ACE inhibitors
and/or ARBs within 24 hours prior to repair and intraoperative hypotension (SBP <100mmHg)
and associated treatments. The results of this analysis add to the existing research available to
provide further guidance on best practice among AAA repair patients. Unfortunately, no solid
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significant associations were identified, and further research is required to inform evidence-based
decision making.
Our study has many strengths. The data used for this analysis were prospectively collected in the
largest randomized controlled trial among AAA repair studies. The RCT minimized outcome
misclassification using adjudicated outcomes. The results are generalizable across Canada as the
RCT was conducted in multiple centres. This was one of the first studies to look at treatments for
intraoperative hypotension which is a proposed area of future interest amongst prior research.
Our results were limited by a lack of power for the analyses. The definition of intraoperative
hypotension could have been further limited to more severe measures of SBP; however, we were
limited by the available data in the RCT. We also looked at intraoperative hypotension as a sole
measure rather than trends during the repair to consider duration and further granularity of this
metric may have provided us with more insight into its potential relationship with AKI. The dose
of ACE inhibitors or ARBs was also not taken into consideration and this may have further
modified their effect.

3.5

Conclusion

We found no evidence to suggest that there is a statistically significant association between
patients who received an ACE inhibitor and/or ARB within 24 hours of repair and postoperative
AKI compared with patients who did not. Our results suggest there may be an association
between intraoperative hypotension, its method of treatment and AKI however this is not
conclusive and worthy of further study in a RCT.
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Chapter 4

4

Systematic review and meta-analysis of preventive strategies for
acute kidney injury in patients undergoing elective abdominal
aortic aneurysm repair

4.1

Introduction

Acute kidney injury (AKI) is a frequent complication after abdominal aortic aneurysm (AAA)
repair.1 Proposed mechanisms of AKI following AAA repair include renal ischemia due to aortic
cross clamping in open repair, use of nephrotoxic medications including contrast in endovascular
aortic aneurysm repair (EVAR), and atheroembolization to the kidney during either procedure.1,2
Patients who demonstrate post-operative AKI have a high risk of morbidity, mortality, a long
length of hospital stay, and high healthcare costs; some patients never recover and are left with
new chronic kidney disease or end-stage kidney disease.1,3–6 AKI incidence after EVAR ranges
from 1% to 19% ; 1,7–9 while AKI incidence after open aortic aneurysm repair ranges from 2% to
29.9%.5,7,10–19 The incidence, rate and severity of AKI across reported studies may be
underestimated.20,21
Effective methods to prevent postoperative AKI among patients undergoing elective
AAA repair have not been well established. Previous systematic reviews have examined AKI in
AAA repair patients but have focused on only one population of open or endovascular repair, or
on all vascular surgery patients and were limited by varying definitions of AKI across included
studies.15,22,23 None of the currently available systematic reviews has completed a review of all
preventive interventions but have focused on a single intervention of interest such as mannitol.24.
This review was conducted to identify preventive interventions for AKI among elective AAA
repair patients in RCTs.
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4.2

Methods

Protocol and Registration
The protocol for this review is published on PROSPERO. The registration ID is
CRD42018100310 and is available at
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=100310.
Information Sources and Search
We searched Medline OVID (1966 - 2018), EMBASE (1947 – 2018), CINAHL (1961 – 2018),
Web of Science (1945 – 2018), Scopus (1966 - 2018), and The Cochrane Library (1996 – 2018)
for all relevant articles. The search strategy was developed with the assistance of an expert
librarian (J.C.) and included terms relating to or describing elective AAA repair and AKI
(Appendix A1). The search terms were adapted for use with each database. ProQuest
Dissertations and Theses Global, Clinicaltrials.gov and ICTRP – WHO were searched for grey
literature relevant to the review. Reference lists and all bibliographic data of retrieved articles
were screened for relevant studies. Two reviewers (M.F. and M.M.) independently screened the
results and those considered potentially relevant by any reviewer were retrieved for full-text
review.
Study Selection and Eligibility
Databases were searched for any published English manuscripts of relevant studies available on
the search date (October 19th, 2018). Randomized controlled trials (RCTs) involving adult
patients undergoing elective abdominal aortic aneurysm repair by the open and/or the
endovascular procedure (juxtarenal, suprarenal, pararenal and infrarenal) were included. Studies
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involving ruptured aneurysms or thoracoabdominal aneurysm were excluded, as were studies
involving a mixed patient population for example including patients treated for aortic occlusive
disease. The review focused on preventive interventions for AKI administered anytime pre-,
intra- or post-operatively.
Comparators of interventions were another intervention, placebo or standard care. Outcomes
included in the review were incidence of AKI measured by serum creatinine (SCr), creatinine
clearance (CrCl) or using the Kidney Disease: Improving Global Outcomes (KDIGO), Risk,
Injury, Failure, Loss, End-Stage Kidney Disease (RIFLE) or Acute Kidney Injury Network
(AKIN) criteria, incidence of renal replacement therapy and mortality.25–27 Any discrepancy in
study inclusion was resolved by consensus or appeal to a third reviewer (L.D.).
Data Extraction
The data extraction was carried out by two independent reviewers (M.F. and M.M.) using a
standardized form. The eligibility of the study was recorded including the inclusion and
exclusion criteria. The methods of the study recorded by the reviewers included the sample size,
the study design, the study location, and the follow up. Patient information recorded by the
reviewers included age, sex, baseline characteristics and comorbidities such as previous RRT.
The interventions and the related information from before and after treatment, and intervention
side effects, were also collected. The comparability of groups, confounding factors and methods
of adjustment, multiple effect estimates (both adjusted and unadjusted) and sources of funding
were collected. The outcome information collected included the number of events, the primary
outcomes, the cost-data utilities and the secondary outcomes. The extracted data were combined
and presented in a table of study characteristics (Table 4-1).
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Risk of Bias
The studies included in this systematic review were limited to randomized controlled trials
(RCTs). The RCTs were assessed using the Cochrane collaboration risk of bias tool (CCRBT). 28
CCRBT assesses the quality of an RCT using 6 classifications: sequence generation, allocation
concealment, blinding, incomplete outcome data, selective outcome reporting, and other
potential threats to validity. The classifications were assessed as low, high and unclear risks of
bias. If all classifications were assessed as having low risk of bias, the overall study was
classified as having low risk of bias. If two classifications were assessed as high or unclear risk
of bias, the overall study was classified as having a moderate risk of bias. If more than 3
classifications were assessed as high or unclear risk of bias, the study was classified as having
high risk of bias (Table 4-3). Study quality was assessed by two independent reviewers.
Between-study risk of bias was not assessed for publication bias due to the small number of
studies available for meta-analysis.29–31
Data Analysis
Where we could, we pooled studies using techniques that accounted for within- and betweenstudy heterogeneity by using a random effects model using RevMan (Review Manager (RevMan)
[Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2014.). Heterogeneity of treatment effects between studies were assessed with the
Cochrane Q and the I2 statistics.32
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4.3

Results

Retrieval of Studies
Our search resulted in 5428 citations retrieved from the following databases: Ovid Medline
(1066), Ovid EMBASE (2604), Scopus (1107), Web of Science (367), CINAHL (80), The
Cochrane Library (176), Dissertations and Theses Global, clinicaltrials.gov and ICTRP-WHO
(28). A total of 1856 duplicate articles were removed from review. A total of 209 articles were
removed as they were not available in English. The reference lists of relevant articles were
reviewed for additional material (Figure 4-I). A total of 27 studies were identified for full-text
screening. A total of 17 studies (1443 number of patients) met eligibility criteria for inclusion in
this review (Table 4-1).
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Figure 4-1 PRISMA flow chart of study selection
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Table 4-1 Characteristics of included studies

Source

Turner et
al, 200733

Garg et
al, 201834

Intervention

Methylprednisolone

Curcumin

UK

patients

18

EVAR/Open

patient

Male

(%)

age,

(%)

years

100% Open

70

NA

Canada

606

EVAR/47%

76

83%

Open
Multi-antioxidant

al, 200235

supplementation

200136

Origin

of

Mean

53%

Wijnen et

Lau et al,

Country of

Number

Netherlands

42

100% Open

69

93%

Ireland

20

100% Open

72

95%

Brazil

36

100% EVAR

71

83%

UK

58

100% EVAR

75

79%

Italy

100

100% Open

68

100%

Extraperitoneal vs
Transperitoneal
Approach

de
Almeida

Carbon Dioxide

Mendes et

Contrast Medium

al, 201737
Saratzis

Sodium

et al,

Bicarbonate and

201838

Hydration

Bonazzi
et al,
200239

Haemodynamic
optimization

67

Mahmood
et al,
200740

Hydroxyethyl

UK

62

100% Open

72

81%

Mannitol

Greece

86

100% EVAR

72

98%

N-acetylcysteine

UK

20

100% EVAR

72

100%

Japan

40

100% Open

71

88%

72

NA

starch vs gelatine

Kalimeris
et al,
201441
Moore et
al, 200642
Mitaka et

human Atrial

al, 200843

Natriuretic Peptide

Mouton

Remote ischemic

et al,

preconditioning

201544

(RIPC)

Murphey

Remote ischemic

et al,

preconditioning

201445

(RIPC)

Walsh et
al, 200946

Walsh et
al, 201047

Ali et al,
200748

65%
UK

69

EVAR/35%
Open

Ireland

62

100% Open

72

86%

UK

40

100% EVAR

75

62%

UK

40

100% Open

74

85%

UK

82

100% Open

75

93%

Remote ischemic
preconditioning
(RIPC)
Remote ischemic
preconditioning
(RIPC)
Remote ischemic
preconditioning
(RIPC)

68

Li et al,
201349

Remote ischemic
preconditioning

China

62

100% Open

65

90%

(RIPC)

Abbreviations: NA = Not Available, EVAR = Endovascular Aneurysm Repair, RIPC= Remote
Ischemic Preconditioning
Study Characteristics
Of the seventeen studies, eleven analyzed: methylprednisolone33, curcumin34, a combination of
antioxidant supplements35, extraperitoneal vs. transperitoneal approach36, carbon dioxide contrast
medium37, sodium bicarbonate38, haemodynamic monitoring39, hydroxyethyl starch40,
mannitol41, N-acetylcysteine42, and human atrial natriuretic peptide43 (Table 4-2). The other six
analyzed the effects of remote ischemic preconditioning44–49 (Table 4-2). The studies were
conducted in the UK (n=8), Canada (n=1), the Netherlands (n=1), Ireland, (n=2), Brazil (n=1),
Italy (n=1), China (n=1), Japan (n=1) and Greece (n=1). The sample size of the studies ranged
from 18 to 606 patients. Three studies had samples of 20 patients or less, five studies had
between 21 and 50 patients, eight studies had between 51 and 100 patients and one study had 606
patients. Of the 17 studies, 15 were single-centre studies. The other two were multi-centre
studies with two and ten centres respectively.34,38 None of the studies was funded by industry
sponsors. The patients in all the studies underwent either an open or endovascular (EVAR)
elective repair. Of the seventeen studies, ten trials involved patients undergoing entirely open
repair (59%), five had entirely EVAR (29%) and two had a mix of open and EVAR repair (12%)
(Table 4-1). Definitions of AKI, AKI stages and renal replacement therapy (RRT) initiation were
different across studies (Table 4-2).
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Table 4-2 Intervention and renal outcome details of included studies
Source

Intervention

Control

Renal

Renal Results

Outcome
Turner et

Methylprednisolone

500mL 5%

al, 200733

10mg/kg prepared in

dextrose

SCr

intervention group

500mL 5% dextrose
Garg et

Curcumin p.o., 2000mg

al, 201834

x 8 doses

Increased SCr for

(P<0.001)
Placebo

AKI, SCr

Higher risk of AKI
(17% vs 10%) for
intervention group
(P=0.01), no
significant betweengroup difference in
SCr rise (1 vs
1umol/L) (P=0.2)

Wijnen et

Multi-antioxidant

Standard

al, 200235

supplementation:

therapy

CrCl, SCr

24 hr CrCl higher on
day 2 for

Vitamin E 200mg qd x 5

intervention group

doses, Vitamin C

(P=0.047), No

2000mg, Allopurinol

significant difference

300mg p.o. day before

in SCr (P>0.05)

surgery and 300mg i.v.
before operation, NAcetylcysteine 150mg/kg
before surgery and
200mg/kg i.v 12 hrs,
Mannitol i.v. 10%
500mg/mL 12hrs at start
of surgery
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Lau et al,

Extraperitoneal

Transperitoneal SCr

SCr significantly

200136

approach

approach

lower on day 1
(P<0.01) and 2
(P<0.05) for
intervention group

de

Carbon Dioxide

Almeida

Iodine Contrast CrCl, AKI

No significant

Medium

difference in CrCl

Mendes et

(P=0.80)

al, 201737
No cases of AKI
Saratzis

1mmol/kg or 1mL/kg of Standard

et al,

an 8.4% Sodium

201838

Bicarbonate solution

AKI

Risk Ratio=0.2 (95%
CI: 0.1 – 0.8)

Hydration

and Hydration
Bonazzi

Haemodynamic

Conventional

Renal failure,

No cases of renal

et al,

optimization

treatment

RRT

failure, no

200239

significant difference
in RRT (P>0.05)

Mahmood Hydroxyethyl starch –

4% Gelatine

SCr

SCr was

et al,

6% HES with a mean

significantly lower

200740

molecular weight of 200

on days 1 (P=0.02),

kDa and a degree of

2 (P=0.045) and 5

hydroxyethyl substitution
of 0.62 OR 6% HES with

(P=0.045) using both
HES solutions

a mean molecular weight
of 130 kDa and a degree
of hydroxyethyl
substitution of 0.4
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Kalimeris

20% Mannitol 0.5 g/kg

Standard

Renal

No significant

et al,

over 15 minutes

Therapy

dysfunction,

difference in renal

SCr

dysfunction

201441

(P=0.30),
SCr lower at 24
hours: mannitol
1.07+/- 0.26 vs.
control 1.20 +/- 0.30
(P<0.05)
Moore et

N-acetylcysteine

Standard fluid

al, 200642

600mg b.i.d orally x 4

hydration

AKI, SCr

No cases of AKI, No
significant

doses

differences in SCr
(P>0.05)

Mitaka et

hANP (0.01–0.05

Placebo

al, 200843

ug/kg/min) infusion

lower (P<0.05)and

prior to cross clamp for

CrCl significantly

48 hours

higher (P<0.05) in

postoperatively

intervention group
Sham cuff

SCr, CrCl

AKI

SCr significantly

Mouton

Remote ischemic

AKIN1: 27% vs

et al,

preconditioning (RIPC)

20%, AKIN2: 21%

201544

– 3 cycles of upper limb

vs 9%, AKIN3: 0%

5 min ischemia/5 min

vs 6%

reperfusion
Murphey

Remote ischemic

Sham cuff

AKI, SCr

No significant

et al,

preconditioning (RIPC)

differences in SCr

201445

– 3 cycles of upper limb

(P>0.05), AKI
(AKIN) 55% vs 36%
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5 min ischemia/5 min

(P=0.12), RRT 23%

reperfusion

vs 0% (P=0.01)

Walsh et

Remote ischemic

Conventional

Renal failure,

No significant

al, 200946

preconditioning (RIPC)

treatment

renal

difference in renal

– 2 sequential periods

impairment,

impairment 22% vs

of lower limb ischemia

SCr

9% (P=0.29), SCr

and reperfusion

(P=0.88), No cases
of renal failure

Walsh et

Remote ischemic

Conventional

Renal failure,

No significant

al, 201047

preconditioning (RIPC)

treatment

renal

difference in SCr

– 2 cycles of common

impairment

(P>0.05), renal

iliac vessel cross-

SCr

failure 18% vs 5.5%

clamping 10 min

(P=0.28) or renal

ischemia/10 min

impairment 50% vs

reperfusion

56% (P=0.73)

Ali et al,

Remote ischemic

Conventional

200748

preconditioning (RIPC)

treatment

AKI, SCr

AKI 7% vs 30%
(P=0.009),

- 2 cycles of common

ORadjusted= 0.2 95%

iliac vessel cross-

CI: 0.1-0.7, (P=0.01)

clamping 10 min
ischemia/10 min
reperfusion
Li et al,

Remote ischemic

201349

preconditioning (RIPC)

Sham cuff

Renal failure,

No cases of renal

RRT

failure or RRT

– 3 cycles of upper limb
5 min ischemia/5 min
reperfusion
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Abbreviations: SCr = Serum Creatinine, AKI = Acute Kidney Injury, CrCl = Creatinine
Clearance, RRT = Renal Replacement Therapy, HES = Hydroxyethyl starch, hANP = human
Atrial Natriuretic Peptide, RIPC = Remote Ischemic Preconditioning, Renal results compared
between groups (interventions vs controls)
Quality
Seven of the studies were at high risk of bias, four were at moderate risk of bias and six were at
low risk of bias (Table 4-3). Three studies (17%) had 0% of patient attrition.43,45,49 Two studies
(12%) had less than 5% of patient attrition 34,44 and four studies (24%) had greater than 5% of
patient attrition 33,38,40,41. The remaining eight studies (47%) did not explicitly discuss attrition in
terms of loss to follow up or exclusion.35–37,39,42,46–48 The assessment of renal function differed
across studies, some reporting as soon as 1, 2, 6, 24 and 48 hours33 following and others on days
1, 3 and 748.
Table 4-3 Risk of bias of included studies
Source

Sequence

Allocation

Generation

Concealment

Blinding

Incomplete

Selective

Other

Outcome

Outcome

Potential

Data

Reporting

Threats to

Overall

Validity
Turner et

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

HIGH

HIGH

HIGH

UNCLEAR

UNCLEAR

UNCLEAR

HIGH

UNCLEAR

UNCLEAR

HIGH

UNCLEAR

UNCLEAR

UNCLEAR

HIGH

al, 200733
Garg et al,
201834
Wijnen et
al, 200235
Lau et al,
200136

74

de

LOW

HIGH

HIGH

UNCLEAR

UNCLEAR

LOW

HIGH

LOW

HIGH

HIGH

HIGH

LOW

LOW

HIGH

LOW

LOW

HIGH

UNCLEAR

LOW

LOW

MODE

Almeida
Mendes et
al, 201737
Saratzis et
al, 201838
Bonazzi et
al, 200239
Mahmood

-RATE
LOW

LOW

HIGH

LOW

HIGH

LOW

et al,

MODE
-RATE

200740
Kalimeris

LOW

LOW

HIGH

HIGH

UNCLEAR

LOW

HIGH

LOW

HIGH

HIGH

UNCLEAR

UNCLEAR

LOW

HIGH

HIGH

HIGH

HIGH

LOW

UNCLEAR

LOW

HIGH

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

HIGH

UNCLEAR

LOW

LOW

MODE

et al,
201441
Moore et
al, 200642
Mitaka et
al, 200843
Mouton et
al, 201544
Murphey
et al,
201445
Walsh et
al, 200946
Walsh et
al, 201047

-RATE
LOW

LOW

HIGH

UNCLEAR

LOW

LOW

MODE
-RATE

75

Ali et al,

LOW

LOW

LOW

UNCLEAR

LOW

LOW

LOW

LOW

LOW

LOW

UNCLEAR

LOW

LOW

LOW

200748
Li et al,
201349

AKI
The incidence of AKI was reported as a dichotomous outcome in four studies, as a continuous
outcome in five studies and as both dichotomous and continuous in eight studies. The reported
renal outcomes were different across all studies with five studies reporting renal function in
terms of SCr or CrCl, five studies reporting renal failure/impairment/dysfunction and seven
studies reporting AKI using various definitions. Mannitol, a composite of antioxidant
supplements, sodium bicarbonate, an open extraperitoneal approach, hANP and HES with
crystalloid have been shown to reduce AKI or improve renal function (Table 4-2).35,36,38,40,41,43
Serum creatinine was significantly lower at 24 hours between mannitol and control groups
(n=86, P<0.05), with no significant difference between groups in renal dysfunction (P=0.30).
The multi-antioxidant supplements had significantly higher CrCl on postoperative day 2
compared to the control group (n=42, P=0.047). The patients that received sodium bicarbonate
and standard hydration had 0.21 times the risk of AKI, compared to patients that received
standard hydration alone (n=58, relative risk = 0.2, 95% CI 0.1 – 0.9). Serum creatinine was
significantly lower on postoperative day 1 and 2 in patients that had an extraperitoneal approach
compared to those that had a transperitoneal approach (n=20, P<0.01, P<0.05). Mean SCr
concentrations were significantly lower on postoperative days 1,2 and 3 among the hANP group
compared to placebo (n=40, P<0.05) and CrCl was significantly higher in the hANP group
compared to the placebo group (P<0.05). The HES solutions had significantly lower SCr on days
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1, 2 and 5 postoperatively, compared to gelatine (n=62, P=0.02, P=0.045, P=0.045). These
results indicate a possible protective effect for AKI.
The results for all relevant interventions are presented in Table 4-2. 33,34,37,39,42–49
Methylprednisolone, curcumin, carbon dioxide contrast medium, haemodynamic monitoring, and
N-acetylcysteine were not associated with a reduction in AKI or improvement in renal function
(Table 4-2).33,34,37,39,42 Methylprednisolone was found to increase SCr (n=18, P<0.001),
indicating an adverse effect on postoperative renal function.33 Curcumin was found to have a
higher incidence of AKI in the intervention group (17% vs. 10%, P=0.01) and no significant
difference between groups regarding the perioperative change in SCr (n=606, P=0.2).34 Carbon
dioxide contrast medium, haemodynamic monitoring, and N-acetylcysteine did not indicate a
statistically significant difference in renal function between groups.37,39,42
RIPC is the remote application, for example a pressure cuff applied to an upper or lower
limb, for a period of ischemia followed by a period of reperfusion in an effort to provide
systemic protection against cellular injury during the ischemic episode, in this case AAA repair.
The 6 studies of 355 patients investigating RIPC were pooled in a meta-analysis (Figure 4-2).44–
49

The results show no statistically significant difference between RIPC and standard treatment

in reducing the incidence of postoperative AKI (OR 1.2, 95% CI 0.4, 3.9). This should be
interpreted with caution due to considerable statistical heterogeneity (Q=9.96, df=3, I2=70%)
(Figure 4-2).44–49
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Figure 4-2 Forest plot comparing remote ischemic preconditioning with control on the
effect on acute kidney injury
Renal Replacement Therapy
The incidence of RRT was reported in 13 studies consisting of 1385 patients.34,37,42,44–49 None of
the studies reported predefined criteria for initiation of RRT among patients. No clear benefit
was found supporting any intervention in any study for reducing the incidence of RRT among
elective AAA repair patients and none of the trials was adequately powered to study this
outcome. Murphey et al reported a significantly greater number of patients that required RRT
among the RIPC intervention group following open elective AAA repair compared to the control
group (7 vs 0, P=0.01).45 Of the seven patients requiring RRT, six required a secondary surgical
intervention which was associated with the initiation of RRT. They postulate this finding may be
due to chance as the study was not powered to detect a difference for this outcome. 45
Mortality
Mortality was reported in 16 of 17 studies comprised of 1345 patients.33–37,39–49 Fifteen of the
sixteen studies considered death as a single end point and one study included death as a
composite end point.34 No clear benefit was found supporting any intervention for reducing
mortality and none of the trials was adequately powered to study this outcome.
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4.4

Discussion

This systematic review demonstrates the paucity of well-designed RCTs evaluating preventive
interventions for AKI in elective AAA repair patients. The trials generally were small, singlecentre, clinically and methodologically diverse resulting in statistical heterogeneity, of low
methodological quality and underpowered to detect differences in AKI, mortality or RRT. The
parameters used to define AKI were primarily in serum creatinine or creatinine clearance with
few defining AKI using the RIFLE or AKIN criteria.25,26 Only one of the studies used the
recently described KDIGO criteria.38 Clinically important endpoints of mortality or RRT were
not considered primary endpoints in most of the studies, as the trials did not have adequate
statistical power to meaningfully look at this outcome. Analysis of the trials did identify a few
interventions that may possibly be associated with beneficial protective effects for the prevention
of AKI.
Possible protective effects were identified for mannitol, a composite of antioxidant
supplements, sodium bicarbonate, an open extraperitoneal approach, hANP and HES combined
with crystalloid for the prevention of AKI postoperatively. Although HES has been shown to be
possibly beneficial in one trial included in this review it has largely gone out of favour in the
clinical community. This is based on contraindicating evidence found in larger, well powered
studies involving critically ill patients which have found a negative effect of starch solutions on
mortality and RRT.50,51 Sodium bicarbonate has also been shown to be possibly beneficial in one
trial included in this review, however, there may be a lack of enthusiasm for this intervention
given large RCTs that demonstrated no benefit for sodium bicarbonate for the prevention of
death, RRT, or contrast-associated AKI among patients undergoing angiography.52 Mannitol, the
composite of anti-oxidant supplements, an open extraperitoneal approach and hANP show
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promise for future RCT investigation. The results presented were based on small, low quality,
high risk of bias RCTs and the effects of these interventions should be further investigated using
large, high quality, multi-centre RCTs.
No evidence of effect was found for the other interventions; however, the majority of
studies were underpowered to detect a difference. The curcumin RCT was the largest trial with
606 patients included in the analysis.34 AKI was found to be significantly higher in the group
receiving curcumin (P=0.01), indicating the importance of investigating herbal supplements and
the associated adverse effects that often go unknown or unpublished.34
The meta-analysis of RCTs examining the RIPC intervention indicates no significant
difference between RIPC and control. The trials were single-centre, small in size (40 to 82
patients) and of low to moderate risk of bias. Meta-analysis of these trials was limited by
statistical heterogeneity which was mainly due to a single study showing benefit for RIPC. In
examining the study’s clinical characteristics, we cannot identify an obvious reason for the
discrepant findings when compared to the other studies which were all negative. We suspect that
RIPC is not effective in the prevention of AKI however future trials should be well powered, use
a defined protocol and use appropriate definitions of AKI.
Future research must consider a variety of factors when designing and conducting RCTs
in this setting. Significant risk factors associated with AKI have been studied indicating that the
development of AKI may be multifactorial. The preventive interventions related to these risk
factors could be administered at once or in succession to study multiple interventions. Future
trials should be designed according to how well powered they are to detect certain endpoints as
previously suggested in a systematic review in the cardiac surgery setting.53 Surrogate endpoints
such as AKI defined by SCr using KDIGO criteria or changes in relevant biomarkers should be
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used in smaller trials in Phase I or II of development. Clinically relevant and critically important
hard endpoints such as mortality, RRT, length of hospitalization and long-term outcomes
including CKD or mortality should be used in well powered trials in phase III or IV of
development. Studies should be designed to include patients with CKD, as CKD patients have
the highest absolute risk of peri-operative AKI excluding those with end-stage renal disease
(ESRD) as AKI is less relevant.20,54
Our review has many strengths beginning with a comprehensive search of the relevant
literature of over 5000 studies. The screening, selection, eligibility criteria assessment and data
extraction were completed independently by two reviewers (MF and MM) to minimize bias. We
also limited our inclusion to RCT in order to focus on potentially more impactful studies.
A limitation of this review is the exclusion of non-English studies from consideration.
This resulted in exclusion of 209 studies of the 5428 screened. Some studies have suggested that
exclusion of non-English studies do not bias the effect estimates of meta-analyses.55,56 The trials
that were identified were generally small, single centre, of poor methodological quality and
significantly underpowered. The definitions of AKI were highly variable, and only one of which
used the recently identified KDIGO criteria for AKI definition.27 Future trials should follow the
KDIGO criteria for defining AKI.

4.5

Conclusion

A small number of relevant studies were found, and most were small, single-centre, of low
methodological quality and underpowered to detect differences in AKI, mortality and RRT. The
possible beneficial effects of mannitol, a composite of antioxidant supplements, an open
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extraperitoneal approach and hANP demonstrates the need for investigation into these strategies
in future RCTs. The largest study of 606 patients receiving curcumin preoperatively found higher
rates of AKI in patients receiving the supplement thus highlighting the need to study herbal
supplements carefully to avoid doing harm. Among patients undergoing elective AAA repair, the
lack of available literature for preventive strategies for AKI highlight the need for large, high
quality, multi-centre studies to identify interventions for reducing the incidence of postoperative
AKI, mortality and RRT.
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Chapter 5

5

Integrated Discussion

The objectives of this thesis are revisited integrating the results and conclusions of chapters 1
through 4. The preventive strategies for AKI following AAA repair discussed in this thesis are
summarized and interpreted in sections 5.1 through 5.3 respectively, including: a summary of
findings, the strengths and limitations of this work and proposed future directions.

5.1

Summary of Findings

We explored potential therapeutic targets for the prevention of AKI following AAA repair. We
examined the risk of AKI following AAA repair among patients taking preoperative ACE
inhibitors and/or ARBs within 24 hours of repair. We also examined the risk of AKI following
AAA repair among patients who experience intraoperative hypotension (SBP <100mmHg) and
were subsequently treated with fluids, inotropes/vasopressors or no treatment. In our data set, we
found no significant association between ACE inhibitor and/or ARB immediate preoperative use
and AKI among AAA repair patients (OR=1.3, 95% CI 0.8 – 2.2). We found no significant
association between intraoperative hypotension (SBP < 100mmHg) and associated treatments
and AKI among AAA repair patients in a multivariable logistic regression analysis (No
treatment: OR=2.0 95% CI 0.8 – 4.8, Fluids: OR=1.0 95% CI 0.4 – 2.6, Inotropes/Vasopressors:
OR=1.7 95% CI 0.8 – 3.7). In Chapter 4, we explored preventive strategies for AKI among AAA
repair patients in a systematic review and meta-analysis of RCTs. Interventions that were shown
to have a potential beneficial effect include mannitol, a composite of antioxidant supplements, an
open extraperitoneal approach and human atrial natriuretic peptide.

91

Our finding that ACE inhibitor and/or ARB use within 24 hours of repair were not significantly
associated with AKI among AAA repair patients is somewhat consistent with the literature
available among this patient setting. Zabrocki et al. did not determine a significant association
among this patient setting, however Statius et al determined a significant association between
ACE/ARB use and postoperative AKI (OR 4.1 95% CI 1.4 – 12.1) among 212 EVAR patients.1,2
Pisimisis et al. found a trend towards a possible association however it did not reach statistical
significance (P=0.07).3 There is no clear consensus whether to continue or discontinue ACE
inhibitors and/or ARBs among AAA repair patients. Our analysis would add further evidence
that discontinuing these medications may not be necessary to prevent AKI, however, our analysis
is not definitive.
We identified intraoperative hypotension, particularly when treated with inotropes/vasopressors
rather than fluids, to be associated with higher odds of AKI on bivariate analysis as stated earlier.
This association was not statistically significant when we adjusted for relative covariates,
however, the point estimates remained in the same direction. There is a sound pathophysiologic
rationale that intraoperative hypotension would potentiate AKI development after AAA repair,
and is consistent with prior literature on the subject.4–8 Most studies have found a significant
association with AKI, including Tallgren et al which determined intraoperative hypotension to be
a significant risk factor following multivariable analysis.5 Our study is unique in that we
examined the effect of different methods of treatment for the hypotension (nothing, fluids or
inotropes/vasopressors) and its effects on AKI. Although the evidence is very weak, our results
suggest avoidance of hypotension, and if it occurs treatment with fluids rather than
inotropes/vasopressors, may help reduce the risk of AKI. These speculative findings warrant
further study to confirm these potential preventive effects.
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In Chapter 4, we systematically summarized the existing literature on potential interventions to
reduce AKI after AAA repair including mannitol, a composite of antioxidant supplements, an
open extraperitoneal approach and hANP. Curcumin, methylprednisolone, carbon dioxide
contrast medium, haemodynamic monitoring and N-acetylcysteine were identified to be
ineffective. We meta-analyzed 6 trials studying remote ischemic preconditioning (RIPC) which
showed no statistically significant difference between RIPC and standard treatment (OR 1.2,
95% CI 0.4 - 3.9). The included trials were small, at high risk of bias and inconsistent. This
review identified the large gap in knowledge relevant to effective preventive strategies for this
important complication following AAA repair. Several potential targets were identified, but
larger, well-designed, prospective trials are needed to further guide therapeutic efforts.

5.2

Strengths and Limitations

5.2.1 Strengths
We performed a secondary data analysis of the largest RCT done to date on the topic of AKI and
AAA repair. Our data set is of high quality from a prospectively collected RCT. Our data were
collected across 10 centres in Canada over 4 provinces allowing for generalizability in Canada.
Our variables were all diagnosed by a practitioner and were adjudicated by a third party blinded
to randomization. This strength in our study can help to estimate the true event rate of AKI as
diagnostic codes are known to underestimate the true event rate. Our analysis of intraoperative
hypotension and associated treatments is unique as this information is not available in the
existing literature. AKI was diagnosed according to the KDIGO criteria which has not been used
in most studies.9
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In Chapter 4, our systematic review was performed according to the Cochrane collaboration
handbook and reported using the PRISMA guidelines. A comprehensive search of relevant
literature screened over 5000 studies. The screening, selection, eligibility criteria assessment and
data extraction was completed independently by two reviewers to minimize bias. We limited
included studies to RCTs to focus on potentially more impactful research.

5.2.2 Limitations
In Chapter 3, out secondary data analysis was limited by residual confounding despite the data
being prospectively collected. The data were limited only to Canada and a predominantly white
sample. Our analysis was underpowered, and our exposures of interest were not of main interest
in the initial analysis and this limited the secondary data analysis. The dose of ACE inhibitors
and/or ARBs was not considered and could have an impact on the results. Although we were
able to separate out patients who simply held their ACE inhibitors/ARBs from those who were
not on the medication at all when assessing whether receiving the medication before surgery
made a difference or not in odds of AKI in a subgroup analysis, our multivariable analysis was
significantly underpowered to detect a difference.
Our measure of intraoperative hypotension was restricted to a dichotomous variable (>100 or
<100 systolic BP). We did not take into account the magnitude of the hypotension, nor the
amount of hypotensive time, and as such we did not have the granularity to fully explore the
potential relationship between this measure and AKI. It is possible that had we used more severe
criteria for hypotension (<80 systolic for example) or considered the amount of time the patient
was hypotensive; we may have identified a stronger association between this and AKI. Similarly,
our measure of the interventions used to treat the hypotension were crude and dichotomous
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(fluids: yes or no; inotropes/vasopressors: yes or no) and further granularity here would have also
been beneficial. Unfortunately, we were limited by the data that had been collected. Our data is
also likely to underestimate the effects of intraoperative hypotension as anesthesiologists tend to
underreport negative intraoperative blood pressures instead presenting a “smoother” variation. 10
In Chapter 4, our systematic review and meta-analysis was limited to English studies only and
the studies identified were generally small, single-centre, low quality and underpowered. The
definitions of AKI across studies was highly variable and only one used the recently identified
KDIGO criteria. The poor-quality and paucity of the existing RCT literature thus limited any
firm conclusions we could make regarding effective measures for the prevention of AKI after
AAA repair.

5.3

Conclusion and Future Directions

Among AAA repair patients, we found no evidence to suggest that there is a statistically
significant association between patients who received an ACE inhibitor and/or ARB within 24
hours prior to repair and postoperative AKI compared with patients who did not. The use of ACE
inhibitors or ARBs preoperatively should be evaluated on a case by case basis depending on the
individual patients hypertension preoperatively. Future studies should evaluate the use of these
drugs in a well powered, high quality RCT as they remain a point of interest. Future studies
should consider the timing of administration of ACE/ARBs and their dosage with a defined
protocol. We found no statistically significant association between postoperative AKI with any
treatment for intraoperative hypotension when compared to those without hypotension. A
possible trend across the bivariate and multivariable analyses suggest an association between
inotrope/vasopressor treatment or no treatment with postoperative AKI compared with patients
without intraoperative hypotension. Our data suggests the possibility that fluids would be a better
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treatment option compared with inotropes/vasopressors, but this association should be further
studied in a large, high quality, multi-centre RCT. Future studies should not only consider
treatment of intraoperative hypotension but should also consider the severity and duration of the
hypotensive episode. Our systematic review and meta-analysis has identified a few potential
targets for further study including mannitol, a composite of antioxidant supplements, an open
extraperitoneal approach and hANP. Among patients undergoing elective AAA repair, the lack
of available literature for preventive strategies for AKI highlight the need for large, high quality,
multi-centre RCTs to identify interventions for reducing the incidence of postoperative AKI,
mortality and RRT using appropriate endpoints and definitions of variables.
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6

Appendices

Appendix A: Inclusion and exclusion criteria from the curcumin trial

Inclusion criteria for patients at pre-operative assessment scheduled for an elective repair of an
unruptured AAA (excluding thoracic and thoracoabdominal aneurysms) included: age greater
than 18 years, ability to provide written consent, if the participant is diabetic they were willing
to monitor and record glucose levels at home, and an open repair or an endovascular repair
where the patient had at least one of the following risk factors for post-operative
complications: i) diabetes mellitus treated with insulin or oral hypoglycemic agents, ii) age
greater than 70 years, or iii) an elevated preoperative serum creatinine (> 177 μmol/L (2.0
mg/dL) in men or > 146 μmol/L (1.6 mg/dL) in women). Patients were excluded according to
the following criteria: patients requiring an elective AAA repair expected to occur in ≤ 3 days,
a prior kidney transplant, patients who were pregnant or breastfeeding, current active
gastrointestinal reflux disease, gastrointestinal ulcer, or hepatobiliary disease, evidence of AKI
in the 30 days prior to pre-operative assessment, participating in another study that could
conflict with the intervention or outcomes of the trial, received 1 or more dialysis treatments
(hemodialysis or peritoneal dialysis) in the week prior to assessment, previous participation in
this trial, a history of a major bleeding event in the 6 months prior to assessment, a bleeding
disorder (a diagnosis of hemophilia, von Willibrand disease, platelets <70), an allergy to
turmeric, ginger, curry, cumin, cardamom, yellow or red food coloring, gelatin or cellulose
and a history of hypoglycemia in the 6 months prior to assessment (<3.5 mmol/L or < 135.0
mg/dL).
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Appendix B In depth description of mediation analysis methods
To determine whether to use the traditional mediation approach of Baron and Kenny (1986),
structural equation modeling or the counterfactual approach by Robins and Greenland (1992)
we considered two factors.1,2 The first factor is a possible interaction between the exposure
and mediator which would require the use of the counterfactual approach. However, there was
no significance for the interaction variable modelled using an interaction term in the
multivariable logistic regression adjusting for various confounders (p>0.05). The second factor
being that the mediator and the outcome are binary which requires a method that uses a unified
approach which cannot be satisfied with structural equation modelling. Therefore, mediation
was assessed using the counterfactual framework by Robins and Greenland (1992) with the
definitions developed by VanderWeele and Vansteelandt (2009-2010).3,4 Valeri and
VanderWeele (2013) provided the definitions for binary mediators.5 Confounding is controlled
for using covariates with the regression approach of VanderWeele (2014).6 The
CAUSALMED procedure in SAS fits generalized linear models that have binary distributions
for the outcome and for the mediator. Covariate effects are incorporated in both the outcome
and mediator models. The model estimates are then used to compute various mediator effects
including total effect (TE), controlled direct effect (CDE), natural direct effect (NDE) and
natural indirect effect (NIE) on the odds ratio scale.5,6
1. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological
research: conceptual, strategic and statistical considerations. J. Pers. Soc. Psychol. 1986; 51(6):
1173-1182.
2. Robins JM, Greenland S. Identifiability and exchangeability for direct and indirect effects.
Epidemiology. 1992; 3(2): 143-155.
3. VanderWeele TJ, Vansteelandt S. Conceptual issues concerning mediation, interventions and
composition. Stat Interface.
4. VanderWeele TJ, Vansteelandt S. Odds ratios for mediation analysis for a dichotomous
outcome. Am. J. Epidemiol. 2010; 172(12): 1339-1348.
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5. Valeri L, VanderWeele TJ. Mediation analysis allowing for exposure-mediator interactions
and causal interpretation: theoretical assumptions and implementation with SAS and SPSS
macros. Psychol. Methods. 2013; 18(2): 137-150.
6. VanderWeele TJ. A unification of mediation and interaction: a four-way decomposition.
Epidemiology. 2014; 25(5): 749-761.

100

Appendix C Comparison of baseline, preoperative and operative characteristics between
patients with and without postoperative AKI

Age, (years) mean (SD)
Sex, male, No. (%)
Centre
London
Edmonton
Ottawa
Hamilton
Winnipeg
Sudbury
Toronto – St. Michael’s
Hospital
Toronto – Sunnybrook
Calgary
Montreal
Diabetes mellitus, No. (%)
Hypertension, No. (%)*
Pre-existing chronic kidney disease
(GFR < 60 mL/min/1.73m2)
Repair type performed, No. (%)
Open
EVAR
Aneurysm size, (mm) mean (SD)
Complications**, No. (%)
Death, No. (%)

AKI
N=79
73.5, (8.5)
59 (74.7%)

No AKI
N=522
75.8, (7.8)
437 (83.7%)

27 (34.2%)
21 (26.6%)
13 (16.5%)
4 (5.1%)
3 (3.8%)
5 (6.3%)
3 (3.8%)

180 (34.5%)
155 (29.7%)
38 (7.3%)
47 (9.0%)
31 (5.9%)
17 (3.3%)
15 (2.9%)

2 (2.5%)

14 (2.7%)

1 (1.3%)
0 (0.0%)
19 (24.1%)
70 (88.6%)

14 (2.7%)
11 (2.1%)
125 (24.0%)
387 (74.4%)

P=0.98
P<0.01

36 (45.6%)

155 (29.7%)

P<0.01

61 (77.2%)
18 (22.8%)
57.9, (14.8)
21 (26.6%)
5 (6.4%)

221 (42.3%)
301 (57.7%)
57.5, (11.0)
33 (6.3%)
4 (0.8%)

P<0.0001

P value
P=0.02
P=0.049

P=0.22

P=0.76
P<0.0001
P<0.01

*2 patients missing hypertension information, **Complications include new acute dialysis, myocardial infarction,
percutaneous coronary intervention, coronary artery bypass graft, sepsis, pneumonia, non-fatal cardiac arrest, stroke,
deep vein thrombosis, pulmonary embolism, lower limb amputation, ischemic bowel, congestive heart failure, death
within 30 days of surgery), *** death within 30 days of surgery.
AKI, acute kidney injury, SD, standard deviation, EVAR, endovascular, No., number of patients, frequency.
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Appendix D Further adjustment of multivariable models to account for centre
Adjusted Odds Ratio
(95%

1.3 (0.8 – 2.2)

Adjusted Odds Ratio
– further adjusted for centre
with a random intercept for
each centre
(95% CI)
1.3 (0.7 – 2.3)

No treatment

2.0 (0.8 – 4.8)

1.7 (0.7-4.2)

Fluids

1.0 (0.4 – 2.6)

1.0 (0.4-2.6)

Exposure

ACE/ARB*
SBP <100mmHg**

Inotropes/Vasopressors
1.7 (0.8 – 3.7)
1.8 (0.8-3.9)
* Adjusting for Age, Pre-existing CKD, Repair Type Performed (Open vs. EVAR), DM, HTN, intraoperative SBP <
100 mmHg, and Aneurysm Diameter
** Adjusting for Age, Pre-existing CKD, Repair Type Performed (Open vs. EVAR), DM, HTN, and Aneurysm
Diameter
ACE, angiotensin-converting enzyme inhibitor, ARB, angiotensin II receptor blocker, SBP, systolic blood pressure,
AKI, acute kidney injury, CI, confidence interval, CKD, chronic kidney disease, EVAR, endovascular abdominal
aortic aneurysm repair, DM, diabetes mellitus, HTN, hypertension.

102

Appendix E. Search Strategies for Systematic Review in various databases
Concept

Keywords

Medline

EMBASE

CINAHL

Web of Science

Scopus

Cochrane Library

AKI
Acute kidney injur* OR acute
kidney failure OR acute kidney
insufficienc* OR acute renal
injur* OR Acute renal failure OR
acute renal insufficienc* OR
renal protect* OR renoprotect*
OR kidney protect* OR
nephroprotect* OR reno-protect*
OR nephro-protect*
kidney diseases/ or renal
insufficiency/ or acute kidney
injury/

acute kidney failure/ or kidney
failure/ or kidney disease/ or
renal protection/
(MH "Renal Insufficiency") OR
(MH "Kidney Failure, Acute")
OR (MH "Kidney Diseases")
TS=("Acute kidney injur*" OR
"acute kidney failure" OR "acute
kidney insufficienc*" OR "acute
renal injur*" OR "acute renal
failure" OR "acute renal
insufficienc*" OR “renal
protect*” OR “renoprotect*” OR
“kidney protect*” OR
“nephroprotect*” OR “renoprotect*” OR “nephro-protect*”)
(TITLE-ABS-KEY("Acute
kidney injur*" OR "acute kidney
failure" OR "acute kidney
insufficienc*" OR "acute renal
injur*" OR "acute renal
failure" OR "acute renal
insufficienc*" OR “renal
protect*” OR “renoprotect*” OR
“kidney protect*” OR
“nephroprotect*” OR “renoprotect*” OR “nephro-protect*”))
[mh ^"kidney diseases"] or [mh
^"renal insufficiency"] or [mh
^"acute kidney injury"]

Abdominal Aortic Aneurysm

abdominal aneurysm* OR
abdominal aortic OR
endovascular AAA OR open
AAA OR EVAR OR
endovascular aneurysm*
Aortic Aneurysm, Abdominal/
OR Aortic Aneurysm/
abdominal aortic aneurysm/ or
aortic aneurysm/ or descending
aortic surgery/ or endovascular
aneurysm repair/ or aneurysm
surgery/
(MH "Aortic Aneurysm,
Abdominal") OR (MH "Aortic
Aneurysm")

TS=(“abdominal aneurysm*”
OR “abdominal aortic” OR
“endovascular AAA” OR “open
AAA” OR “EVAR” OR
“endovascular aneurysm*”)

(TITLE-ABS-KEY("abdominal
aneurysm" OR "aortic
aneurysm" OR "endovascular
AAA" OR "open
AAA" OR “EVAR” OR
“endovascular aneurysm*”))
[mh ^"Aortic Aneurysm,
Abdominal"] OR [mh ^"Aortic
Aneurysm"]
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